<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11359700</article-id><article-id pub-id-type="pmcid-ver">PMC11359700.1</article-id><article-id pub-id-type="pmcaid">11359700</article-id><article-id pub-id-type="pmcaiid">11359700</article-id><article-id pub-id-type="pmid">39204073</article-id><article-id pub-id-type="doi">10.3390/vaccines12080950</article-id><article-id pub-id-type="publisher-id">vaccines-12-00950</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-1242-8792</contrib-id><name name-style="western"><surname>Liu</surname><given-names initials="D">Dequan</given-names></name><xref rid="af1-vaccines-12-00950" ref-type="aff">1</xref><xref rid="fn1-vaccines-12-00950" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="L">Lei</given-names></name><xref rid="af1-vaccines-12-00950" ref-type="aff">1</xref><xref rid="fn1-vaccines-12-00950" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">Xinghan</given-names></name><xref rid="af2-vaccines-12-00950" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-1140-9858</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="S">Shijin</given-names></name><xref rid="af1-vaccines-12-00950" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="G">Guangzhen</given-names></name><xref rid="af1-vaccines-12-00950" ref-type="aff">1</xref><xref rid="c1-vaccines-12-00950" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4646-1390</contrib-id><name name-style="western"><surname>Che</surname><given-names initials="X">Xiangyu</given-names></name><xref rid="af1-vaccines-12-00950" ref-type="aff">1</xref><xref rid="c1-vaccines-12-00950" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Skwarczynski</surname><given-names initials="M">Mariusz</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Hussein</surname><given-names initials="W">Waleed</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Shalash</surname><given-names initials="AO">Ahmed O.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-00950"><label>1</label>Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China; <email>liudq@dmu.edu.cn</email> (D.L.); <email>liuleidmu1989@163.com</email> (L.L.); <email>wangsj01@dmu.edu.cn</email> (S.W.)</aff><aff id="af2-vaccines-12-00950"><label>2</label>Department of Stomatology, General Hospital of Northern Theater Command, Shenyang 110016, China; <email>lxh950601@163.com</email></aff><author-notes><corresp id="c1-vaccines-12-00950"><label>*</label>Correspondence: <email>wuguangzhen@firsthosp-dmu.com</email> (G.W.); <email>chexiangyu@firsthosp-dmu.com</email> (X.C.)</corresp><fn id="fn1-vaccines-12-00950"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2024</year></pub-date><volume>12</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">469603</issue-id><elocation-id>950</elocation-id><history><date date-type="received"><day>28</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>09</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>30</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-01 13:25:13.907"><day>01</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-12-00950.pdf"/><abstract><p>With the continuous advancements in tumor immunotherapy, researchers are actively exploring new treatment methods. Peptide therapeutic cancer vaccines have garnered significant attention for their potential in improving patient outcomes. Despite its potential, only a single peptide-based cancer vaccine has been approved by the U.S. Food and Drug Administration (FDA). A comprehensive understanding of the underlying mechanisms and current development status is crucial for advancing these vaccines. This review provides an in-depth analysis of the production principles and therapeutic mechanisms of peptide-based cancer vaccines, highlights the commonly used peptide-based cancer vaccines, and examines the synergistic effects of combining these vaccines with immunotherapy, targeted therapy, radiotherapy, and chemotherapy. While some studies have yielded suboptimal results, the potential of combination therapies remains substantial. Additionally, we addressed the management and adverse events associated with peptide-based cancer vaccines, noting their relatively higher safety profile compared to traditional radiotherapy and chemotherapy. Lastly, we also discussed the roles of adjuvants and targeted delivery systems in enhancing vaccine efficacy. In conclusion, this review comprehensively outlines the current landscape of peptide-based cancer vaccination and underscores its potential as a pivotal immunotherapy approach.</p></abstract><kwd-group><kwd>peptide-based cancer vaccines</kwd><kwd>mechanism of action</kwd><kwd>combination therapy</kwd><kwd>medication administration</kwd><kwd>adjuvants</kwd><kwd>delivery systems</kwd></kwd-group><funding-group><award-group><funding-source>the Horizontal Project Department Fund of the First Affiliated Hospital of Dalian Medical University</funding-source><award-id>2022CR015</award-id></award-group><award-group><funding-source>the Liaoning Provincial Education Department</funding-source><award-id>JYTMS20230577</award-id></award-group><funding-statement>This project is supported by the Horizontal Project Department Fund of the First Affiliated Hospital of Dalian Medical University (No. 2022CR015) and the Liaoning Provincial Education Department (No. JYTMS20230577).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-00950"><title>1. Introduction</title><p>The concept of immunotherapy dates back to the late 19th century when William Coley, a New York surgeon, observed that infections in cancer patients could occasionally lead to tumor regression [<xref rid="B1-vaccines-12-00950" ref-type="bibr">1</xref>]. This observation led to the development of Coley&#8217;s toxins, who had been exploiting streptococcus-mediated tumor rejection, a form of early immunotherapy [<xref rid="B2-vaccines-12-00950" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-12-00950" ref-type="bibr">3</xref>]. The identification of tumor antigens in the late 20th century was a pivotal moment for cancer vaccines [<xref rid="B4-vaccines-12-00950" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-00950" ref-type="bibr">5</xref>]. Tumor antigens are proteins or peptides presented on the surface of cancer cells that can be recognized by the immune system [<xref rid="B6-vaccines-12-00950" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-00950" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-00950" ref-type="bibr">8</xref>]. This discovery led to the idea that vaccines could be developed to stimulate the immune system to recognize and attack tumors based on these antigens [<xref rid="B6-vaccines-12-00950" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-00950" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-00950" ref-type="bibr">8</xref>]. Peptide-based cancer vaccines are designed to specifically target these tumor antigens, aiming to elicit a strong and specific immune response against cancer cells [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>].</p><p>Peptide-based cancer vaccines have emerged as a promising strategy in cancer immunotherapy [<xref rid="B10-vaccines-12-00950" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-00950" ref-type="bibr">11</xref>]. Peptide-based cancer vaccines work by inducing an immune response against specific tumor-associated antigens (TAAs) derived from mutated or overexpressed proteins in cancer cells [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>,<xref rid="B11-vaccines-12-00950" ref-type="bibr">11</xref>]. These vaccines are designed to be recognized by the immune system, particularly cytotoxic T lymphocytes (CTLs), which can then target and kill cancer cells presenting these antigens [<xref rid="B12-vaccines-12-00950" ref-type="bibr">12</xref>]. The first peptide-based cancer vaccines were developed in the 1990s, with initial trials focusing on melanoma, namely melanoma antigen gene-1 (MAGE-1)-derived peptide-based cancer vaccines [<xref rid="B13-vaccines-12-00950" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-12-00950" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-00950" ref-type="bibr">15</xref>]. Specifically, the researchers found that human melanoma cells can process the MAGE-1 gene product and present the processed nonapeptide EADPTGHSY on their human leukocyte antigen (HLA)-A1 molecules as a determinant for CTLs [<xref rid="B15-vaccines-12-00950" ref-type="bibr">15</xref>]. Immunizing melanoma patients, whose tumor cells express the MAGE-1 gene and who are HLA-A1+, with cultured autologous antigen-presenting cells pulsed with the synthetic nonapeptide-induced autologous melanoma-reactive and nonapeptide-specific CTLs in situ at the immunization site and at distant metastatic sites demonstrated the potential of peptide vaccines in cancer immunotherapy [<xref rid="B13-vaccines-12-00950" ref-type="bibr">13</xref>,<xref rid="B15-vaccines-12-00950" ref-type="bibr">15</xref>]. Early clinical trials explored the immunogenicity and therapeutic potential of peptides derived from melanoma-associated antigens [<xref rid="B16-vaccines-12-00950" ref-type="bibr">16</xref>]. These studies laid the groundwork for understanding how peptide vaccines could be optimized for better immune response.</p><p>Despite facing challenges such as variability in patient responses and the need for enhanced targeting, ongoing research is dedicated to overcoming these obstacles through novel adjuvants, combination therapies, and personalized vaccine strategies [<xref rid="B10-vaccines-12-00950" ref-type="bibr">10</xref>,<xref rid="B17-vaccines-12-00950" ref-type="bibr">17</xref>]. Combining peptide vaccines with immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies, has shown promising results by counteracting the immunosuppressive tumor microenvironment [<xref rid="B18-vaccines-12-00950" ref-type="bibr">18</xref>]. Additionally, combining peptide vaccines with conventional therapies like chemotherapy and radiation has been explored to modulate the tumor microenvironment and enhance the efficacy of immunotherapy [<xref rid="B19-vaccines-12-00950" ref-type="bibr">19</xref>]. Strategies such as using neoantigens and incorporating multi-epitope peptides to target multiple pathways aim to overcome tumor heterogeneity [<xref rid="B17-vaccines-12-00950" ref-type="bibr">17</xref>]. Despite the challenges and limited clinical successes, peptide-based therapeutic cancer vaccines remain a hopeful avenue in cancer treatment. Sipuleucel-T (Provenge) was approved by the FDA in April 2010, developed by Dendreon Corporation, and is designed to stimulate an immune response against prostate cancer using the patient&#8217;s dendritic cells loaded and activated with a fusion protein [<xref rid="B20-vaccines-12-00950" ref-type="bibr">20</xref>]. Sipuleucel-T, an autologous active cellular immunotherapy, demonstrated efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer [<xref rid="B20-vaccines-12-00950" ref-type="bibr">20</xref>]. The phase 3 trial revealed a 22% relative reduction in the risk of death for patients treated with Sipuleucel-T compared to a placebo, translating to a 4.1-month improvement in median survival [<xref rid="B20-vaccines-12-00950" ref-type="bibr">20</xref>]. Although Sipuleucel-T is not a traditional peptide vaccine, it utilizes a recombinant fusion protein that includes prostatic acid phosphatase, a prostate antigen, linked to an immune cell activator (GM-CSF) [<xref rid="B20-vaccines-12-00950" ref-type="bibr">20</xref>]. This brings hope to relevant researchers. A better understanding of the immune response, optimization of vaccine formulations, and strategic combinations with other therapies are crucial for developing the next generation of these vaccines [<xref rid="B10-vaccines-12-00950" ref-type="bibr">10</xref>]. In this review, we examine the production processes and mechanisms of action of peptide tumor vaccines and provide an overview of various peptide-based therapeutic cancer vaccines. Additionally, we discuss the opportunities and challenges encountered in their clinical application.</p></sec><sec id="sec2-vaccines-12-00950"><title>2. The Current Status of Peptide Vaccine Development: Promising Potential Amidst Challenges</title><p>The general rate of success of cancer peptide vaccines, in terms of overall survival (OS) and progression-free survival (PFS), has been variable and generally modest [<xref rid="B21-vaccines-12-00950" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-00950" ref-type="bibr">22</xref>]. For instance, in a phase 3 randomized trial, patients with advanced melanoma treated with the gp100 peptide vaccine and interleukin-2 showed a significantly higher overall clinical response rate (16% vs. 6%) and longer PFS (2.2 vs. 1.6 months) compared to those receiving interleukin-2 alone [<xref rid="B21-vaccines-12-00950" ref-type="bibr">21</xref>]. The study, involving 185 patients, demonstrated a median OS of 17.8 months for the vaccine-interleukin-2 group compared to 11.1 months for the interleukin-2-only group [<xref rid="B21-vaccines-12-00950" ref-type="bibr">21</xref>]. Meanwhile, in a recent placebo-controlled trial, 53 participants received the MUC1 peptide vaccine, while 50 received a placebo to prevent recurrent colorectal adenoma [<xref rid="B22-vaccines-12-00950" ref-type="bibr">22</xref>]. Thirteen of fifty-two (25%) vaccine recipients exhibited a significant immune response, and among these immune responders, a 38% absolute reduction in adenoma recurrence was observed compared to the placebo group [<xref rid="B22-vaccines-12-00950" ref-type="bibr">22</xref>]. Despite these outcomes, peptide vaccines generally exhibit less impressive results compared to other immunotherapies [<xref rid="B23-vaccines-12-00950" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-00950" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-00950" ref-type="bibr">25</xref>]. For instance, immune checkpoint inhibitors have demonstrated higher response rates in clinical trials for solid tumors, including non-small cell lung cancer, renal cell carcinoma, and melanoma [<xref rid="B26-vaccines-12-00950" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-12-00950" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-12-00950" ref-type="bibr">28</xref>].</p><p>In summary, due to the unsatisfactory performance of peptide vaccines in clinical trials and various inherent challenges and limitations, the FDA has approved only one peptide vaccine for cancer treatment: Sipuleucel-T (Provenge) [<xref rid="B29-vaccines-12-00950" ref-type="bibr">29</xref>]. First and foremost, the primary limitation of peptide vaccines is their low immunogenicity, which means they typically do not elicit strong immune responses independently [<xref rid="B17-vaccines-12-00950" ref-type="bibr">17</xref>]. This is partly due to the short length of the peptides, which may not be sufficient to activate robust T-cell responses [<xref rid="B17-vaccines-12-00950" ref-type="bibr">17</xref>]. Enhancing immunogenicity through potent adjuvants, longer peptides, and peptide cocktails can boost immune responses [<xref rid="B17-vaccines-12-00950" ref-type="bibr">17</xref>,<xref rid="B30-vaccines-12-00950" ref-type="bibr">30</xref>]. Another challenge is that peptide vaccines are usually designed to bind to specific HLA (human leukocyte antigen) molecules [<xref rid="B31-vaccines-12-00950" ref-type="bibr">31</xref>]. If only a single target peptide is used for vaccination, immune escape may occur [<xref rid="B32-vaccines-12-00950" ref-type="bibr">32</xref>]. Additionally, because HLA molecules vary greatly between individuals, a peptide vaccine effective for one person may not be effective for another, limiting its universal applicability [<xref rid="B33-vaccines-12-00950" ref-type="bibr">33</xref>]. To address this, current strategies include designing vaccines that contain multiple epitopes capable of binding to different HLA molecules, thereby increasing the likelihood of benefiting a broader patient population [<xref rid="B32-vaccines-12-00950" ref-type="bibr">32</xref>,<xref rid="B34-vaccines-12-00950" ref-type="bibr">34</xref>]. Additionally, developing personalized vaccines tailored to the HLA characteristics of individual patients can enhance the effectiveness of peptide vaccines [<xref rid="B35-vaccines-12-00950" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-12-00950" ref-type="bibr">36</xref>].</p></sec><sec id="sec3-vaccines-12-00950"><title>3. Mechanism of Action of Peptide Cancer Vaccines</title><p>Peptide-based cancer vaccines work by stimulating the immune system to target and destroy cancer cells [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>]. Researchers select specific antigens that are overexpressed or unique to cancer cells, synthesize peptides that represent these antigens, and then formulate these peptides with adjuvants to enhance the immune response [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>]. Once administered, antigen-presenting cells (APCs) present these peptides to T cells, activating them to attack cancer cells and potentially form memory T cells to prevent recurrence [<xref rid="B10-vaccines-12-00950" ref-type="bibr">10</xref>,<xref rid="B37-vaccines-12-00950" ref-type="bibr">37</xref>]. The mechanism of action of peptide-based cancer vaccines involves a series of steps designed to elicit an immune response against cancer cells (<xref rid="vaccines-12-00950-f001" ref-type="fig">Figure 1</xref>).</p><sec id="sec3dot1-vaccines-12-00950"><title>3.1. Selection of Target Antigens</title><p>Key considerations in designing peptide vaccines include optimizing peptide length, selecting highly immunogenic epitopes, and balancing B-cell and T-cell responses [<xref rid="B38-vaccines-12-00950" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-12-00950" ref-type="bibr">39</xref>]. Overcoming the immunosuppressive tumor microenvironment (TME) is crucial for the efficacy of peptide vaccines [<xref rid="B40-vaccines-12-00950" ref-type="bibr">40</xref>]. Potent adjuvants are critical for enhancing the immunogenicity of peptide vaccines, which can stimulate innate immune responses, leading to the activation of dendritic cells and the subsequent priming of T cells [<xref rid="B41-vaccines-12-00950" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-12-00950" ref-type="bibr">42</xref>]. Meanwhile, peptide vaccines employ various types of peptides, including linear peptides, modified peptides, and peptides of different lengths, to effectively target cancer cells [<xref rid="B43-vaccines-12-00950" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-12-00950" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-12-00950" ref-type="bibr">45</xref>]. Linear peptides are straightforward sequences designed to stimulate specific immune responses, while modified peptides undergo chemical alterations to enhance stability, binding affinity, and immunogenicity [<xref rid="B43-vaccines-12-00950" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-12-00950" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-12-00950" ref-type="bibr">45</xref>]. Short peptides (8&#8211;10 amino acids) typically target T-cell epitopes to elicit cytotoxic responses, whereas long peptides (20&#8211;30 amino acids) can contain multiple epitopes to stimulate both CD4+ and CD8+ T cells [<xref rid="B46-vaccines-12-00950" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-12-00950" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-12-00950" ref-type="bibr">48</xref>]. Multi-epitope peptides and neoantigen peptides tailored to tumor-specific mutations provide broader and more personalized immune responses, respectively [<xref rid="B39-vaccines-12-00950" ref-type="bibr">39</xref>,<xref rid="B48-vaccines-12-00950" ref-type="bibr">48</xref>]. However, there is the potential for autoimmunity and immune escape, especially for TAAs, as the immune system may attack normal cells expressing these antigens [<xref rid="B41-vaccines-12-00950" ref-type="bibr">41</xref>,<xref rid="B49-vaccines-12-00950" ref-type="bibr">49</xref>]. In contrast, tumor-specific antigens (TSAs) that specifically target cancer cells pose less risk [<xref rid="B49-vaccines-12-00950" ref-type="bibr">49</xref>]. Tumor immune escape through antigen mutation or downregulation, as well as tumor heterogeneity, complicate vaccine efficacy for both TAA and TSA vaccines [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>]. Developing vaccines against neoantigens requires a personalized approach, which is more complex and costly but offers greater specificity and a reduced risk of autoimmunity [<xref rid="B50-vaccines-12-00950" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-12-00950" ref-type="bibr">51</xref>]. Additionally, direct tumor targeting through intratumoral injection can focus the immune response within the TME [<xref rid="B50-vaccines-12-00950" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-12-00950" ref-type="bibr">51</xref>]. These strategies are essential for developing effective peptide vaccines capable of overcoming the TME and eliciting a strong, targeted immune response against cancer cells.</p><p>Advances in high-throughput sequencing and mass spectrometry have led to the identification of numerous TAAs and TSAs [<xref rid="B52-vaccines-12-00950" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-12-00950" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-12-00950" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-12-00950" ref-type="bibr">55</xref>]. TAAs are proteins or peptides overexpressed in cancer cells compared to normal cells, including examples like carcinoembryonic antigen (CEA) and prostate-specific antigen (PSA) [<xref rid="B56-vaccines-12-00950" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-12-00950" ref-type="bibr">57</xref>]. TSAs, arising from mutations, are unique to cancer cells, exemplified by neoantigens from Kirsten rat sarcoma viral oncogene homolog (KRAS) or p53 mutations [<xref rid="B58-vaccines-12-00950" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-12-00950" ref-type="bibr">59</xref>]. Bioinformatics tools have significantly improved the prediction of immunogenic epitopes and their binding to major histocompatibility complex (MHC) molecules, facilitating the selection of peptides capable of eliciting robust immune responses [<xref rid="B60-vaccines-12-00950" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-12-00950" ref-type="bibr">61</xref>]. For example, Nielsen and Andreatta discussed the NetMHCpan-3.0 tool, which enhances peptide-binding prediction to MHC class I molecules, while Jespersen et al. highlighted the BepiPred-2.0 tool for improved B-cell epitope prediction [<xref rid="B62-vaccines-12-00950" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-12-00950" ref-type="bibr">63</xref>]. Additionally, advanced genomic and proteomic technologies, like next-generation sequencing and mass spectrometry, play crucial roles in identifying potential antigens and validating their immunogenicity [<xref rid="B64-vaccines-12-00950" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-12-00950" ref-type="bibr">65</xref>]. Robbins et al. demonstrated the use of next-generation sequencing to identify mutated antigens recognized by tumor-reactive T cells [<xref rid="B66-vaccines-12-00950" ref-type="bibr">66</xref>]. Enhanced peptide synthesis and validation processes, including MHC binding assays and T-cell activation tests, have increased the reliability of candidate peptides [<xref rid="B67-vaccines-12-00950" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-12-00950" ref-type="bibr">68</xref>]. Ongoing innovations in neoantigen discovery, supported by advancements in artificial intelligence and machine learning, continue to enhance the efficacy and applicability of peptide-based cancer vaccines [<xref rid="B17-vaccines-12-00950" ref-type="bibr">17</xref>,<xref rid="B69-vaccines-12-00950" ref-type="bibr">69</xref>]. Peptides representing these antigens are synthetically optimized for stability, immune recognition, and MHC molecule binding, aiming to induce a robust and specific immune response against cancer cells while minimizing autoimmunity or tolerance issues [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-12-00950" ref-type="bibr">10</xref>,<xref rid="B37-vaccines-12-00950" ref-type="bibr">37</xref>] (<xref rid="vaccines-12-00950-f001" ref-type="fig">Figure 1</xref>). Common tumor antigens and their respective characteristics in recent years are shown in <xref rid="vaccines-12-00950-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec3dot2-vaccines-12-00950"><title>3.2. Vaccine Formulation</title><p>The peptide synthesis, typically through solid-phase peptide synthesis, efficiently assembles the amino acid sequence [<xref rid="B87-vaccines-12-00950" ref-type="bibr">87</xref>]. The peptides then undergo purification, often via high-performance liquid chromatography (HPLC), to remove impurities, and are characterized to confirm their identity and purity using methods like mass spectrometry and analytical HPLC [<xref rid="B88-vaccines-12-00950" ref-type="bibr">88</xref>]. To enhance the immune response, the peptides are formulated with adjuvants [<xref rid="B30-vaccines-12-00950" ref-type="bibr">30</xref>,<xref rid="B89-vaccines-12-00950" ref-type="bibr">89</xref>]. Adjuvants are chosen for their ability to enhance the immune response, including aluminum salts, incomplete Freund&#8217;s adjuvant (IFA), and MF59, which are selected to enhance the immune response by stimulating the innate immune system and facilitating antigen presentation [<xref rid="B30-vaccines-12-00950" ref-type="bibr">30</xref>,<xref rid="B89-vaccines-12-00950" ref-type="bibr">89</xref>]. Delivery systems such as liposomes, nanoparticles, and emulsions are utilized to protect peptides from degradation, ensure targeted delivery, and facilitate uptake by antigen-presenting cells [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>,<xref rid="B90-vaccines-12-00950" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-12-00950" ref-type="bibr">91</xref>,<xref rid="B92-vaccines-12-00950" ref-type="bibr">92</xref>]. The formulation must also address peptide stability, optimizing conditions to prevent degradation. Factors affecting immunogenicity include the mode of administration, dose, and dosing schedule [<xref rid="B30-vaccines-12-00950" ref-type="bibr">30</xref>,<xref rid="B93-vaccines-12-00950" ref-type="bibr">93</xref>]. The final product, formulated as a liquid for injection or lyophilized for reconstitution, is typically administered via subcutaneous, intradermal, or intramuscular injection, depending on the specific vaccine design [<xref rid="B91-vaccines-12-00950" ref-type="bibr">91</xref>,<xref rid="B92-vaccines-12-00950" ref-type="bibr">92</xref>]. Additionally, formulations are developed with an eye toward regulatory standards and manufacturability, ensuring the vaccine can be produced at scale and meet safety, efficacy, and quality benchmarks [<xref rid="B94-vaccines-12-00950" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-12-00950" ref-type="bibr">95</xref>] (<xref rid="vaccines-12-00950-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec3dot3-vaccines-12-00950"><title>3.3. Presentation and T-Cell Activation in Peptide-Based Cancer Vaccines</title><p>The presentation of antigens by APCs such as dendritic cells and macrophages is essential for initiating immune responses against cancer through peptide-based vaccines [<xref rid="B96-vaccines-12-00950" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-12-00950" ref-type="bibr">97</xref>]. Internalized peptides are processed into smaller fragments and presented on MHC class I or class II molecules on the surface of APCs, which then migrate to lymphoid organs to present these complexes to T cells, thereby initiating adaptive immune responses [<xref rid="B98-vaccines-12-00950" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-12-00950" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-12-00950" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-12-00950" ref-type="bibr">101</xref>]. T-cell activation involves the interaction between the T-cell receptor (TCR) on the T cell and the peptide&#8211;MHC complex on the APC, along with necessary co-stimulatory signals [<xref rid="B102-vaccines-12-00950" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-12-00950" ref-type="bibr">103</xref>]. CD8+ T cells differentiate into CTLs that can directly kill cancer cells, while CD4+ T cells secrete cytokines to enhance immune responses [<xref rid="B98-vaccines-12-00950" ref-type="bibr">98</xref>,<xref rid="B100-vaccines-12-00950" ref-type="bibr">100</xref>]. Immunological memory, mediated by central and effector memory T cells, enables the immune system to rapidly recognize and combat previously encountered cancer cells (<xref rid="vaccines-12-00950-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec3dot4-vaccines-12-00950"><title>3.4. Enhancing CTL Response Induction</title><p>Cytotoxic T-lymphocyte (CTL) responses are crucial for anti-tumor immunity within peptide-based cancer vaccines, but their induction requires precise antigen delivery mechanisms [<xref rid="B104-vaccines-12-00950" ref-type="bibr">104</xref>]. Dendritic cells (DCs) are pivotal, capturing and cross-presenting tumor antigens on MHC class I molecules to activate CTLs [<xref rid="B35-vaccines-12-00950" ref-type="bibr">35</xref>]. Enhancing CTL responses involves the use of adjuvants and cytokines to boost DC function [<xref rid="B41-vaccines-12-00950" ref-type="bibr">41</xref>,<xref rid="B105-vaccines-12-00950" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-12-00950" ref-type="bibr">106</xref>]. For instance, in a phase I clinical trial, a peptide vaccination emulsified in IFA successfully elicited leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia (CLL) [<xref rid="B107-vaccines-12-00950" ref-type="bibr">107</xref>]. Meanwhile, adjuvants for peptide vaccines are essential for eliciting robust anti-tumor CD4+ T-cell responses [<xref rid="B108-vaccines-12-00950" ref-type="bibr">108</xref>]. For instance, the combination of synthetic peptides with Toll-like receptor (TLR) agonists and OX40/CD40 co-stimulation has been shown to produce significant anti-tumor effects in a mouse model of malignant melanoma [<xref rid="B108-vaccines-12-00950" ref-type="bibr">108</xref>]. Additionally, immune checkpoint inhibitors prevent negative regulatory signals, reinvigorating CTLs [<xref rid="B109-vaccines-12-00950" ref-type="bibr">109</xref>]. Combination therapies enhance CTL efficacy by increasing tumor antigen release and susceptibility of tumor cells to immune attack [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>]. Advanced delivery systems, such as nanoparticles, improve antigen presentation and CTL induction [<xref rid="B35-vaccines-12-00950" ref-type="bibr">35</xref>]. Together, these strategies aim to enhance the anti-tumor immunity of peptide tumor vaccines.</p></sec><sec id="sec3dot5-vaccines-12-00950"><title>3.5. Cold Chain Transport</title><p>Maintaining an effective cold chain is critical for the stability and effectiveness of peptide tumor vaccines, particularly in resource-limited settings where inconsistencies during transportation and storage can compromise efficacy [<xref rid="B110-vaccines-12-00950" ref-type="bibr">110</xref>]. Regulatory oversight and the use of electronic and chemical monitoring devices are essential to mitigate risk and ensure a robust cold chain [<xref rid="B110-vaccines-12-00950" ref-type="bibr">110</xref>]. These regions face significant challenges, including unreliable electricity, limited refrigeration, difficult terrain, extreme climates, and funding constraints [<xref rid="B111-vaccines-12-00950" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-12-00950" ref-type="bibr">112</xref>]. Addressing these challenges requires strategies such as developing thermostable vaccine formulations, investing in health infrastructure, fostering partnerships, and providing training and capacity building to support reliable cold chain systems [<xref rid="B111-vaccines-12-00950" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-12-00950" ref-type="bibr">112</xref>]. For instance, in Tunisia, continuous temperature monitoring combined with other technological interventions significantly reduced the prevalence of accidental vaccine freezing [<xref rid="B113-vaccines-12-00950" ref-type="bibr">113</xref>]. The incidence of freeze alarms at health center levels dropped by 40%, and the risk of freezing during transport decreased from 13.8% to 1.7%, demonstrating the effectiveness of temperature monitoring in protecting vaccine potency [<xref rid="B113-vaccines-12-00950" ref-type="bibr">113</xref>]. Additionally, peptides in lyophilized form are chemically stable even at ambient temperatures, eliminating the need for continuous cold chain storage and transportation required for traditional vaccines [<xref rid="B114-vaccines-12-00950" ref-type="bibr">114</xref>]. These findings underscore the importance of developing robust cold chain transportation systems for peptide tumor vaccines.</p></sec></sec><sec id="sec4-vaccines-12-00950"><title>4. Current Peptide-Based Cancer Vaccines</title><p>Common peptide-based cancer vaccines currently in clinical practice and trials include GV1001 targeting hTERT in pancreatic and NSCLC (non-small-cell lung cancer), IMA901 for renal cell carcinoma, HER2/neu peptide vaccines like NeuVax and GP2 for breast cancer, NY-ESO-1 vaccines for melanoma and ovarian cancer, WT1 vaccines for leukemia and mesothelioma, and MAGE-A3 vaccines for melanoma and NSCLC [<xref rid="B115-vaccines-12-00950" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-12-00950" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-12-00950" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-12-00950" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-12-00950" ref-type="bibr">119</xref>,<xref rid="B120-vaccines-12-00950" ref-type="bibr">120</xref>,<xref rid="B121-vaccines-12-00950" ref-type="bibr">121</xref>,<xref rid="B122-vaccines-12-00950" ref-type="bibr">122</xref>,<xref rid="B123-vaccines-12-00950" ref-type="bibr">123</xref>]. Recently, a novel intranasal peptide vaccine significantly inhibited NSCLC in an inducible mutant KRAS-mouse lung tumor model [<xref rid="B124-vaccines-12-00950" ref-type="bibr">124</xref>]. The immunized animals showed decreased CD4 + FoxP3 + T cells, increased interferon (IFN)-&#947; and IL-17a levels, enhanced KRAS-specific Th1 and Th17 responses, and significantly reduced tumor incidence compared to controls [<xref rid="B124-vaccines-12-00950" ref-type="bibr">124</xref>]. More information about peptide-based cancer vaccines is shown in <xref rid="vaccines-12-00950-t002" ref-type="table">Table 2</xref>. Due to tumor heterogeneity and immune escape mechanisms, peptide vaccines are rarely used as monotherapy [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>]. Tumor heterogeneity, including intratumoral and intertumoral variability, results in diverse subpopulations of cancer cells with distinct genetic and phenotypic characteristics, making it difficult for a single vaccine to target all tumor cells effectively [<xref rid="B40-vaccines-12-00950" ref-type="bibr">40</xref>,<xref rid="B125-vaccines-12-00950" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-12-00950" ref-type="bibr">126</xref>]. Immune escape mechanisms, such as antigen loss, altered antigen presentation, creation of an immunosuppressive microenvironment, and upregulation of immune checkpoint molecules, further diminish the efficacy of vaccines [<xref rid="B40-vaccines-12-00950" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-12-00950" ref-type="bibr">41</xref>]. These factors lead to limited efficacy, incomplete tumor eradication, and potential relapse when vaccines are used alone [<xref rid="B38-vaccines-12-00950" ref-type="bibr">38</xref>]. The current focus is on identifying suitable combination therapies, as well as developing effective adjuvants and delivery systems [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>].</p></sec><sec id="sec5-vaccines-12-00950"><title>5. Peptide-Based Cancer Vaccines Combination Therapy: A Promising Approach</title><p>Combination therapy involving peptide-based cancer vaccines leverages the synergistic effects of multiple treatment modalities to enhance the immune response against tumors [<xref rid="B17-vaccines-12-00950" ref-type="bibr">17</xref>,<xref rid="B19-vaccines-12-00950" ref-type="bibr">19</xref>]. By combining peptide-based cancer vaccines with immune checkpoint inhibitors, the immune system&#8217;s ability to recognize and destroy cancer cells is significantly improved [<xref rid="B18-vaccines-12-00950" ref-type="bibr">18</xref>,<xref rid="B148-vaccines-12-00950" ref-type="bibr">148</xref>,<xref rid="B149-vaccines-12-00950" ref-type="bibr">149</xref>,<xref rid="B150-vaccines-12-00950" ref-type="bibr">150</xref>]. This approach helps to overcome the immunosuppressive environment often created by tumors, thereby boosting the efficacy of the vaccines [<xref rid="B148-vaccines-12-00950" ref-type="bibr">148</xref>,<xref rid="B151-vaccines-12-00950" ref-type="bibr">151</xref>]. Additionally, integrating peptide-based cancer vaccines with conventional therapies like chemotherapy and radiation can modulate the tumor microenvironment, making it more conducive to an immune attack [<xref rid="B152-vaccines-12-00950" ref-type="bibr">152</xref>,<xref rid="B153-vaccines-12-00950" ref-type="bibr">153</xref>,<xref rid="B154-vaccines-12-00950" ref-type="bibr">154</xref>,<xref rid="B155-vaccines-12-00950" ref-type="bibr">155</xref>,<xref rid="B156-vaccines-12-00950" ref-type="bibr">156</xref>]. Ongoing research and clinical trials continue to explore and refine these combination therapies, aiming to establish them as standard treatment options in oncology [<xref rid="B153-vaccines-12-00950" ref-type="bibr">153</xref>] (<xref rid="vaccines-12-00950-f002" ref-type="fig">Figure 2</xref>).</p><sec id="sec5dot1-vaccines-12-00950"><title>5.1. Combination Therapy with Targeted Therapy and Immunotherapy</title><p>There are few studies on the combination of peptide-based cancer vaccines and targeted therapies, and experiments have shown that the effect of this combination therapy is modest [<xref rid="B117-vaccines-12-00950" ref-type="bibr">117</xref>]. In 2016, in a multicenter, open-label, randomized, controlled phase 3 trial, Rini et al. evaluated the efficacy of the IMA901 peptide-based cancer vaccine plus sunitinib versus sunitinib alone as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT) [<xref rid="B117-vaccines-12-00950" ref-type="bibr">117</xref>]. The study found that the combination of IMA901 and sunitinib did not significantly improve OS compared to sunitinib alone [<xref rid="B117-vaccines-12-00950" ref-type="bibr">117</xref>]. While the vaccine induced strong immune responses, the median OS was similar between both groups, indicating that further development of IMA901 requires enhancement of its immune response magnitude [<xref rid="B117-vaccines-12-00950" ref-type="bibr">117</xref>].</p><p>Compared with the combination with targeted therapy, researchers have conducted more in-depth research on the combination of peptide-based cancer vaccines and immunotherapy, and the progress achieved has been more significant [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>]. By combining peptide-based cancer vaccines with immunotherapy drugs, the vaccines can better prime and expand T cells, leading to a more potent and sustained anti-tumor effect [<xref rid="B42-vaccines-12-00950" ref-type="bibr">42</xref>,<xref rid="B157-vaccines-12-00950" ref-type="bibr">157</xref>,<xref rid="B158-vaccines-12-00950" ref-type="bibr">158</xref>]. Immunotherapy can modulate the tumor microenvironment, reducing immunosuppressive cells like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), thus enhancing the function and infiltration of effector T cells [<xref rid="B158-vaccines-12-00950" ref-type="bibr">158</xref>,<xref rid="B159-vaccines-12-00950" ref-type="bibr">159</xref>,<xref rid="B160-vaccines-12-00950" ref-type="bibr">160</xref>]. This synergy is in line with the principles of personalized medicine and optimizing treatment efficacy [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>] (<xref rid="vaccines-12-00950-f002" ref-type="fig">Figure 2</xref>).</p><p>As early as the late 1990s, Disis et al. demonstrated the generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine [<xref rid="B149-vaccines-12-00950" ref-type="bibr">149</xref>]. The vaccine included peptides derived from the HER-2/neu extracellular and intracellular domains, mixed with granulocyte macrophage colony-stimulating factor as an adjuvant, to elicit a CD4 T-helper-specific immune response [<xref rid="B149-vaccines-12-00950" ref-type="bibr">149</xref>]. All patients immunized with HER-2/neu peptides developed peptide-specific T-cell responses, with the majority also showing protein-specific responses and potential for tumor site migration [<xref rid="B149-vaccines-12-00950" ref-type="bibr">149</xref>]. Subsequently, more clinical trials verified the superiority of the combination of immunotherapy drugs and peptide-based cancer vaccines. In 2010, in a phase 3 study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00094653">NCT00094653</ext-link>) conducted by Hodi et al., ipilimumab, an anti-CTLA-4 antibody, was evaluated for its efficacy in improving OS in patients with metastatic melanoma [<xref rid="B150-vaccines-12-00950" ref-type="bibr">150</xref>]. The study involved 676 patients who were randomly assigned to receive either ipilimumab plus the gp100 peptide vaccine, ipilimumab alone, or the gp100 peptide vaccine alone [<xref rid="B150-vaccines-12-00950" ref-type="bibr">150</xref>]. The results demonstrated that the median OS was significantly longer in the group receiving the combination of ipilimumab and the gp100 peptide vaccine (10.0 months) compared to the group receiving the gp100 peptide vaccine alone (6.4 months). This suggests that the combination of the gp100 peptide vaccine with immunotherapy can enhance survival outcomes for patients with metastatic melanoma [<xref rid="B150-vaccines-12-00950" ref-type="bibr">150</xref>]. Similarly, combining the HPV16-specific vaccine ISA101 with the anti-PD-1 antibody nivolumab demonstrated promising efficacy in a phase 2 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02426892">NCT02426892</ext-link>) for patients with incurable HPV-16-positive cancer in 2019 [<xref rid="B161-vaccines-12-00950" ref-type="bibr">161</xref>]. The study enrolled 24 patients and reported an overall response rate of 33%, with a median OS of 17.5 months, suggesting enhanced tumoricidal effects compared to PD-1 inhibition alone [<xref rid="B161-vaccines-12-00950" ref-type="bibr">161</xref>]. These results indicate potential benefits of combining therapeutic vaccines with immune checkpoint inhibitors (<xref rid="vaccines-12-00950-f002" ref-type="fig">Figure 2</xref>). The detailed experimental contents are summarized in <xref rid="vaccines-12-00950-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec5dot2-vaccines-12-00950"><title>5.2. Combination Therapy with Chemotherapy</title><p>The combination of chemotherapy and peptide-based tumor vaccines has shown promising results in enhancing anti-tumor immune responses and improving clinical outcomes for cancer patients [<xref rid="B163-vaccines-12-00950" ref-type="bibr">163</xref>]. This synergistic approach leverages the cytotoxic effects of chemotherapy to reduce tumor burden and modulate the tumor microenvironment, making it more conducive to immune activation, while peptide-based vaccines specifically target tumor-associated antigens to elicit robust immune responses [<xref rid="B165-vaccines-12-00950" ref-type="bibr">165</xref>]. Chemotherapy can increase the immunogenicity of tumors by inducing immunogenic cell death, which releases tumor antigens and danger signals that enhance the recruitment and activation of APCs [<xref rid="B165-vaccines-12-00950" ref-type="bibr">165</xref>]. This process is crucial for the efficacy of peptide-based vaccines, as it amplifies the presentation of tumor antigens in the context of major histocompatibility complex (MHC) molecules, thereby improving the activation of CTLs [<xref rid="B166-vaccines-12-00950" ref-type="bibr">166</xref>]. Tumors often create an immunosuppressive microenvironment that hinders effective immune responses. Chemotherapeutic agents such as cyclophosphamide and paclitaxel can deplete Tregs and MDSCs, which are key players in immune suppression within the tumor microenvironment [<xref rid="B167-vaccines-12-00950" ref-type="bibr">167</xref>]. By reducing the population of these immunosuppressive cells, chemotherapy enhances the efficacy of peptide-based vaccines, allowing for more robust activation and proliferation of effector T cells [<xref rid="B168-vaccines-12-00950" ref-type="bibr">168</xref>] (<xref rid="vaccines-12-00950-f002" ref-type="fig">Figure 2</xref>).</p><p>Several studies have investigated the efficacy of combining peptide tumor vaccines with chemotherapy, yielding mixed results. In 2011, Slingluff et al. conducted a multicenter randomized trial to evaluate the effects of melanoma-associated helper peptides and cyclophosphamide (CY) on the immunogenicity of a multipeptide melanoma vaccine [<xref rid="B155-vaccines-12-00950" ref-type="bibr">155</xref>]. Involving 167 patients with resected stage IIB to IV melanoma, the trial revealed that melanoma-associated helper peptides paradoxically decreased CD8(+) T-cell responses, while CY pretreatment had no significant immunologic or clinical effect [<xref rid="B155-vaccines-12-00950" ref-type="bibr">155</xref>]. Similarly, in 2014, the TeloVac trial by Middleton et al. assessed the efficacy of the telomerase peptide vaccine GV1001 combined with gemcitabine and capecitabine in 1062 patients with locally advanced or metastatic pancreatic cancer [<xref rid="B141-vaccines-12-00950" ref-type="bibr">141</xref>]. This study found that adding GV1001 to chemotherapy did not significantly improve OS compared to chemotherapy alone, highlighting the need for new strategies to enhance immune responses during chemotherapy [<xref rid="B141-vaccines-12-00950" ref-type="bibr">141</xref>]. In another study, Weller et al. evaluated the combination of rindopepimut and temozolomide in a randomized, double-blind, international phase 3 trial involving 745 patients with newly diagnosed, EGFRvIII-expressing glioblastoma [<xref rid="B140-vaccines-12-00950" ref-type="bibr">140</xref>]. The trial showed no significant difference in OS between the treatment groups, indicating that rindopepimut did not increase survival [<xref rid="B140-vaccines-12-00950" ref-type="bibr">140</xref>]. Conversely, in 2017, Hijikata et al. conducted a phase I trial on RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors, showing potential clinical efficacy with stable disease in six out of ten patients and an increase in tumor-reactive CD8+ T cells [<xref rid="B162-vaccines-12-00950" ref-type="bibr">162</xref>]. Additionally, in 2017, Shirahama et al. reported positive outcomes in a randomized phase II trial of personalized peptide vaccination (PPV) combined with low-dose cyclophosphamide (CPA) in advanced biliary tract cancer patients, demonstrating significantly improved PFS and OS compared to PPV alone, suggesting the potential benefit of CPA in enhancing PPV efficacy by preventing IL-6-mediated immune suppression [<xref rid="B163-vaccines-12-00950" ref-type="bibr">163</xref>]. While these studies highlight the complexity of combining peptide tumor vaccines with chemotherapy, they also illustrate the potential of this combination therapy (<xref rid="vaccines-12-00950-f002" ref-type="fig">Figure 2</xref>). The detailed experimental contents are summarized in <xref rid="vaccines-12-00950-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec5dot3-vaccines-12-00950"><title>5.3. Combination Therapy with Radiotherapy</title><p>Combining peptide tumor vaccines with radiation therapy leverages the complementary mechanisms of both treatments to enhance anti-tumor efficacy [<xref rid="B48-vaccines-12-00950" ref-type="bibr">48</xref>]. Radiation therapy can induce immunogenic cell death, releasing TAAs and facilitating their uptake by APCs such as dendritic cells, thereby boosting the immune system&#8217;s response [<xref rid="B165-vaccines-12-00950" ref-type="bibr">165</xref>,<xref rid="B169-vaccines-12-00950" ref-type="bibr">169</xref>]. Radiation also enhances the expression of MHC class I molecules and co-stimulatory molecules on tumor cells and APCs, improving antigen presentation to T cells [<xref rid="B169-vaccines-12-00950" ref-type="bibr">169</xref>,<xref rid="B170-vaccines-12-00950" ref-type="bibr">170</xref>]. This strategic combination enhances T-cell activation and proliferation, leading to potentially improved clinical outcomes in cancer immunotherapy [<xref rid="B171-vaccines-12-00950" ref-type="bibr">171</xref>,<xref rid="B172-vaccines-12-00950" ref-type="bibr">172</xref>] (<xref rid="vaccines-12-00950-f002" ref-type="fig">Figure 2</xref>).</p><p>In recent years, the combination of peptide tumor vaccines with radiotherapy has shown promising results in clinical trials. In 2014, Iinuma et al. conducted a phase I clinical study combining a multiple epitope peptide vaccine with chemoradiation therapy (CRT) in patients with unresectable esophageal squamous cell carcinoma (ESCC) [<xref rid="B156-vaccines-12-00950" ref-type="bibr">156</xref>]. This study involved 11 HLA-A positive patients who received a vaccine comprising five peptides (TTK, URLC10, KOC1, VEGFR1, and VEGFR2) alongside CRT [<xref rid="B156-vaccines-12-00950" ref-type="bibr">156</xref>]. The treatment was well tolerated and induced peptide-specific cytotoxic T-lymphocyte responses in all patients, with six patients achieving complete response (CR) and four maintaining long-term CR for up to 4.6 years, suggesting potential efficacy for unresectable ESCC [<xref rid="B156-vaccines-12-00950" ref-type="bibr">156</xref>]. Similarly, in 2017, Shen et al. conducted a phase I clinical study to evaluate the efficacy and safety of PPV combined with radiotherapy in patients with advanced hepatocellular carcinoma (HCC) [<xref rid="B164-vaccines-12-00950" ref-type="bibr">164</xref>]. Nine patients with advanced HCC, including those with multiple metastases, were treated with precise radiotherapy and PPV-based cellular immune therapy, leading to significant decreases in AFP levels and partial responses in three patients, with stable disease in three others [<xref rid="B164-vaccines-12-00950" ref-type="bibr">164</xref>]. This combined therapy was well tolerated, with no significant liver, kidney, or severe hematological side effects observed, indicating its feasibility and effectiveness as a treatment strategy for advanced HCC [<xref rid="B164-vaccines-12-00950" ref-type="bibr">164</xref>]. The integration of radiotherapy and peptide-based tumor vaccines represents a promising strategy to enhance anti-tumor immunity and improve clinical outcomes, offering more effective and durable tumor control (<xref rid="vaccines-12-00950-f002" ref-type="fig">Figure 2</xref>). The detailed experimental contents are summarized in <xref rid="vaccines-12-00950-t003" ref-type="table">Table 3</xref>.</p></sec></sec><sec id="sec6-vaccines-12-00950"><title>6. Administration and Monitoring Protocols</title><p>Initially, patients undergo eligibility screening and baseline measurements to determine their suitability for treatment [<xref rid="B11-vaccines-12-00950" ref-type="bibr">11</xref>]. Vaccines are administered via subcutaneous or intradermal injections. Typically, the vaccination schedule includes an initial series of doses followed by booster injections [<xref rid="B10-vaccines-12-00950" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-00950" ref-type="bibr">11</xref>,<xref rid="B37-vaccines-12-00950" ref-type="bibr">37</xref>]. The dosage of peptide-based cancer vaccines can vary, but a common dose is around 1 mg per injection [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>], sometimes combined with low-dose CPA to reduce regulatory T cells, with a dose of 100 mg/day for seven days before vaccination [<xref rid="B163-vaccines-12-00950" ref-type="bibr">163</xref>]. Peptide-based cancer vaccines are administered subcutaneously or intradermally, often with adjuvants such as GM-CSF or IFA to enhance the immune response [<xref rid="B9-vaccines-12-00950" ref-type="bibr">9</xref>,<xref rid="B37-vaccines-12-00950" ref-type="bibr">37</xref>,<xref rid="B173-vaccines-12-00950" ref-type="bibr">173</xref>]. This approach has been used in various cancers, including prostate cancer, for which a poxviral-based PSA vaccine is administered initially every two weeks for the first month, followed by monthly doses [<xref rid="B174-vaccines-12-00950" ref-type="bibr">174</xref>].</p><p>Furthermore, mucosal administration of peptide tumor vaccines has been demonstrated to be easier to manage and more cost-effective, offering a promising approach to elicit strong and localized immune responses [<xref rid="B175-vaccines-12-00950" ref-type="bibr">175</xref>,<xref rid="B176-vaccines-12-00950" ref-type="bibr">176</xref>]. Among them, chitosan-based polyelectrolyte complexes (PECs) have been extensively applied in drug delivery due to their excellent biocompatibility, biodegradability, and bioadhesive properties, making them ideal for mucosal administration [<xref rid="B177-vaccines-12-00950" ref-type="bibr">177</xref>]. Mucosal routes of administration for peptide tumor vaccines, including oral, nasal, sublingual, and other mucosal surfaces, offer significant advantages by eliciting robust and localized immune responses [<xref rid="B178-vaccines-12-00950" ref-type="bibr">178</xref>]. Oral vaccines, often encapsulated in nanoparticles or liposomes, are absorbed through the gut-associated lymphoid tissue, inducing strong mucosal and systemic immunity [<xref rid="B179-vaccines-12-00950" ref-type="bibr">179</xref>,<xref rid="B180-vaccines-12-00950" ref-type="bibr">180</xref>,<xref rid="B181-vaccines-12-00950" ref-type="bibr">181</xref>]. Nasal vaccines target the nasal-associated lymphoid tissue, promoting rapid immune responses [<xref rid="B182-vaccines-12-00950" ref-type="bibr">182</xref>]. Sublingual vaccines, absorbed through the sublingual mucosa, bypass digestive enzymes and induce both local and systemic immunity [<xref rid="B183-vaccines-12-00950" ref-type="bibr">183</xref>]. Sublingual vaccination with the model tumor antigen ovalbumin (OVA) and the synthetic glycolipid alpha-galactosylceramide has been shown to induce both mucosal and systemic adaptive immunity [<xref rid="B183-vaccines-12-00950" ref-type="bibr">183</xref>]. These non-invasive delivery methods enhance patient compliance and improve the efficacy of peptide tumor vaccines by achieving targeted and potent immune responses, making them valuable strategies in cancer immunotherapy [<xref rid="B177-vaccines-12-00950" ref-type="bibr">177</xref>].</p><p>Monitoring involves periodic blood sampling to measure immune responses and imaging studies to track tumor progression [<xref rid="B184-vaccines-12-00950" ref-type="bibr">184</xref>]. Prognostic indicators of treatment success include immune response markers, such as T-cell activation, cytokine profiles, and antibody responses, as well as tumor response indicators, like imaging results and tumor biomarker levels [<xref rid="B185-vaccines-12-00950" ref-type="bibr">185</xref>]. Clinical outcomes are measured through OS, PFS, and quality of life [<xref rid="B11-vaccines-12-00950" ref-type="bibr">11</xref>,<xref rid="B174-vaccines-12-00950" ref-type="bibr">174</xref>,<xref rid="B186-vaccines-12-00950" ref-type="bibr">186</xref>,<xref rid="B187-vaccines-12-00950" ref-type="bibr">187</xref>].</p></sec><sec id="sec7-vaccines-12-00950"><title>7. Adverse Events: Present but Manageable</title><p>One of the most common adverse events reported in peptide-based cancer vaccines trials is injection site reactions, including redness, swelling, pain, and sometimes induration at the injection site [<xref rid="B188-vaccines-12-00950" ref-type="bibr">188</xref>]. These reactions are typically mild to moderate in intensity and resolve on their own without requiring significant medical intervention [<xref rid="B188-vaccines-12-00950" ref-type="bibr">188</xref>]. For instance, in the clinical trial of the HER2/neu peptide-based cancer vaccine (NeuVax) for breast cancer, injection site reactions were among the most frequently observed side effects, often presenting as localized redness and swelling, which generally subsided without further treatment [<xref rid="B119-vaccines-12-00950" ref-type="bibr">119</xref>]. Similarly, studies on the NY-ESO-1 peptide-based cancer vaccine in melanoma and ovarian cancer have documented similar injection site reactions, emphasizing their transient and manageable nature [<xref rid="B121-vaccines-12-00950" ref-type="bibr">121</xref>].</p><p>Meanwhile, peptide-based cancer vaccines can induce various autoimmune symptoms depending on the targeted antigen and the patient&#8217;s predisposition [<xref rid="B186-vaccines-12-00950" ref-type="bibr">186</xref>]. For instance, researchers found that patients with metastatic melanoma treated with a peptide-based cancer vaccine developed vitiligo, characterized by the loss of skin pigmentation due to the immune system attacking melanocytes [<xref rid="B186-vaccines-12-00950" ref-type="bibr">186</xref>]. In some cases, the robust immune activation induced by peptide-based cancer vaccines can lead to a systemic inflammatory response known as cytokine release syndrome (CRS) [<xref rid="B116-vaccines-12-00950" ref-type="bibr">116</xref>,<xref rid="B121-vaccines-12-00950" ref-type="bibr">121</xref>]. CRS is characterized by high fever, hypotension, and multi-organ dysfunction, requiring immediate medical attention [<xref rid="B116-vaccines-12-00950" ref-type="bibr">116</xref>,<xref rid="B121-vaccines-12-00950" ref-type="bibr">121</xref>]. For instance, a phase I trial investigated the efficacy of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeted nanoparticle peptide vaccine for advanced soft tissue sarcoma, treating three patients with refractory synovial sarcoma, two of whom developed CRS with low to moderately elevated cytokine levels [<xref rid="B189-vaccines-12-00950" ref-type="bibr">189</xref>]. Although adverse events still exist, peptide-based cancer vaccines still show good safety compared with traditional chemoradiotherapy [<xref rid="B190-vaccines-12-00950" ref-type="bibr">190</xref>].</p></sec><sec id="sec8-vaccines-12-00950"><title>8. Adjuvants</title><p>Immune adjuvants play a crucial role in peptide-based cancer vaccines by enhancing the body&#8217;s immune response to the administered antigens, working through mechanisms such as stimulating APCs, promoting cytokine release, and inducing strong Th1 and Th2 immune responses [<xref rid="B191-vaccines-12-00950" ref-type="bibr">191</xref>]. Adjuvants like aluminum salts (alum) create depots for slow antigen release, while others like MF59 and AS04 enhance APC recruitment and activation, and some, such as CpG oligodeoxynucleotides (ODNs) and MPL, activate TLRs to stimulate robust cellular and humoral immunity [<xref rid="B30-vaccines-12-00950" ref-type="bibr">30</xref>,<xref rid="B192-vaccines-12-00950" ref-type="bibr">192</xref>,<xref rid="B193-vaccines-12-00950" ref-type="bibr">193</xref>]. A recent study has also highlighted that certain peptides also possess adjuvant properties [<xref rid="B194-vaccines-12-00950" ref-type="bibr">194</xref>]. Specifically, a nanoliposomal vaccine containing the long multi-epitope peptide E75-AE36 combined with PADRE has been shown to induce a robust immune response in the TUBO mouse model of breast cancer [<xref rid="B194-vaccines-12-00950" ref-type="bibr">194</xref>]. This formulation elicited superior CD4+ and CD8+ T-cell responses and significantly enhanced IFN-&#947; production, resulting in a substantial reduction in tumor growth and an increase in lifespan compared to other formulations [<xref rid="B194-vaccines-12-00950" ref-type="bibr">194</xref>]. Meanwhile, GM-CSF enhances the immune response in peptide-based cancer vaccines by promoting dendritic cell differentiation and maturation, improving peptide antigen presentation to T cells, and stimulating pro-inflammatory cytokine secretion, with clinical studies showing that GM-CSF combined with peptide-based cancer vaccines is safe, well tolerated, and effective in increasing T-cell responses and PFS in melanoma patients [<xref rid="B119-vaccines-12-00950" ref-type="bibr">119</xref>,<xref rid="B195-vaccines-12-00950" ref-type="bibr">195</xref>,<xref rid="B196-vaccines-12-00950" ref-type="bibr">196</xref>].</p><sec id="sec8dot1-vaccines-12-00950"><title>8.1. GM-CSF</title><p>GM-CSF is an effective adjuvant for peptide-based cancer vaccines due to its ability to enhance the immune response through promoting the differentiation and maturation of DCs, which are critical for effective antigen presentation and subsequent T-cell activation [<xref rid="B197-vaccines-12-00950" ref-type="bibr">197</xref>,<xref rid="B198-vaccines-12-00950" ref-type="bibr">198</xref>]. Additionally, GM-CSF improves the presentation of peptide antigens to CD4+ and CD8+ T cells, enhances the migration of DCs to lymphoid tissues, and stimulates the secretion of pro-inflammatory cytokines, thereby generating a robust and sustained anti-tumor immune response [<xref rid="B199-vaccines-12-00950" ref-type="bibr">199</xref>,<xref rid="B200-vaccines-12-00950" ref-type="bibr">200</xref>].</p><p>The use of GM-CSF in combination with peptide-based cancer vaccines has shown promise in enhancing the immune response [<xref rid="B119-vaccines-12-00950" ref-type="bibr">119</xref>,<xref rid="B195-vaccines-12-00950" ref-type="bibr">195</xref>,<xref rid="B196-vaccines-12-00950" ref-type="bibr">196</xref>]. Clinical studies have administered GM-CSF at dosages ranging from 75 to 125 &#181;g/m<sup>2</sup> subcutaneously, with minimal severe side effects and favorable safety profiles [<xref rid="B119-vaccines-12-00950" ref-type="bibr">119</xref>,<xref rid="B186-vaccines-12-00950" ref-type="bibr">186</xref>,<xref rid="B195-vaccines-12-00950" ref-type="bibr">195</xref>,<xref rid="B196-vaccines-12-00950" ref-type="bibr">196</xref>]. In a randomized phase II trial, vaccination using four melanoma peptides administered with GM-CSF in adjuvant or pulsed on dendritic cells was evaluated for clinical and immunologic responses [<xref rid="B186-vaccines-12-00950" ref-type="bibr">186</xref>]. The study demonstrated that T-cell responses to melanoma peptides were significantly higher in the GM-CSF arm compared to the dendritic cell arm, with overall immune response favoring the GM-CSF administration [<xref rid="B186-vaccines-12-00950" ref-type="bibr">186</xref>].</p><p>In a study by Atzpodien et al., ten patients with resected stage IIA-IIIC melanoma received individualized adjuvant peptide vaccinations combined with GM-CSF [<xref rid="B195-vaccines-12-00950" ref-type="bibr">195</xref>]. After a mean of 6.5 vaccination cycles, PFS was 6 months, with five patients remaining relapse-free for 1+ to 21+ months [<xref rid="B195-vaccines-12-00950" ref-type="bibr">195</xref>]. The vaccine was well tolerated, with no severe side effects [<xref rid="B195-vaccines-12-00950" ref-type="bibr">195</xref>]. Meanwhile, in the multicenter intergroup randomized placebo-controlled phase III trial E4697, Butterfield et al. investigated the effects of adjuvant GM-CSF and a multi-epitope melanoma peptide-based cancer vaccine on patients with completely resected, high-risk stage III/IV melanoma [<xref rid="B196-vaccines-12-00950" ref-type="bibr">196</xref>]. The study enrolled 815 patients and aimed to promote melanoma-specific CD8 T-cell responses through the use of GM-CSF and the melanoma antigen peptide-based cancer vaccines [<xref rid="B196-vaccines-12-00950" ref-type="bibr">196</xref>]. While the overall recurrence-free survival and OS were not significantly improved, the trial observed immunomodulatory effects, with vaccinated patients showing increased peptide-specific CD8 T-cell responses and patients receiving GM-CSF experiencing reduced percentages of circulating myeloid and plasmacytoid dendritic cells, along with the development of anti-GM-CSF neutralizing antibodies that correlated with improved clinical outcomes [<xref rid="B196-vaccines-12-00950" ref-type="bibr">196</xref>]. These clinical studies demonstrate that peptide-based cancer vaccines combined with GM-CSF are feasible and worthy of further clinical research.</p></sec><sec id="sec8dot2-vaccines-12-00950"><title>8.2. TLR Agonists</title><p>TLR agonists, such as CpG ODNs and imiquimod, enhance the immune response by activating dendritic cells and other antigen-presenting cells, leading to the upregulation of costimulatory molecules and pro-inflammatory cytokine secretion [<xref rid="B201-vaccines-12-00950" ref-type="bibr">201</xref>]. Clinical studies have shown that CpG ODNs, administered at dosages ranging from 0.01 to 5 mg per injection, can enhance antigen-specific T-cell responses when combined with peptide-based cancer vaccines, with side effects generally limited to mild injection site reactions and transient flu-like symptoms [<xref rid="B202-vaccines-12-00950" ref-type="bibr">202</xref>,<xref rid="B203-vaccines-12-00950" ref-type="bibr">203</xref>,<xref rid="B204-vaccines-12-00950" ref-type="bibr">204</xref>]. For instance, a study combining a melanoma peptide-based cancer vaccine with CpG 7909 demonstrated enhanced CD8+ T-cell responses and increased antigen-specific immunity, with manageable side effects [<xref rid="B204-vaccines-12-00950" ref-type="bibr">204</xref>]. Meanwhile, in a study by Thomann et al., liposomal constructs co-delivering peptide epitopes and TLR agonists were developed to induce a specific anti-tumor immune response against ErbB2 protein-expressing tumor cells [<xref rid="B205-vaccines-12-00950" ref-type="bibr">205</xref>]. The researchers found that liposomes containing TLR2/6 agonists were more effective than those with TLR2/1 agonists in eradicating these tumors [<xref rid="B205-vaccines-12-00950" ref-type="bibr">205</xref>]. Additionally, incorporating mannosylated ligands into the liposomes enhanced their therapeutic efficiency, allowing for treatment with lower quantities of both TLR ligands and peptide epitopes [<xref rid="B205-vaccines-12-00950" ref-type="bibr">205</xref>].</p><p>For the overview of commonly used adjuvants in clinical practice and their characteristics, refer to <xref rid="vaccines-12-00950-t004" ref-type="table">Table 4</xref>.</p></sec></sec><sec id="sec9-vaccines-12-00950"><title>9. Targeted Delivery Systems</title><p>Peptide-based cancer vaccines utilize various delivery systems to enhance their stability, targeting, and immunogenicity, including liposomes, polymeric micelle, and gold nanoparticle (AuNP) [<xref rid="B91-vaccines-12-00950" ref-type="bibr">91</xref>,<xref rid="B205-vaccines-12-00950" ref-type="bibr">205</xref>,<xref rid="B212-vaccines-12-00950" ref-type="bibr">212</xref>]. Liposomes and nanoparticles have been shown in numerous preclinical studies to protect peptides from degradation and enhance efficient antigen presentation, underscoring their potential to improve the effectiveness of peptide vaccines [<xref rid="B91-vaccines-12-00950" ref-type="bibr">91</xref>,<xref rid="B205-vaccines-12-00950" ref-type="bibr">205</xref>,<xref rid="B212-vaccines-12-00950" ref-type="bibr">212</xref>,<xref rid="B213-vaccines-12-00950" ref-type="bibr">213</xref>].</p><sec id="sec9dot1-vaccines-12-00950"><title>9.1. Utilizing Ligands for Enhanced Therapeutic Efficacy</title><p>Nanoparticles functionalized with various ligands significantly enhance the targeted delivery of peptide tumor vaccines, for example, folate-conjugated AuNPs, which target cancer cells [<xref rid="B214-vaccines-12-00950" ref-type="bibr">214</xref>]. Additionally, polymeric nanoparticles like RGD-functionalized micelles target integrins on tumor vasculature [<xref rid="B215-vaccines-12-00950" ref-type="bibr">215</xref>]. Moreover, liposomes functionalized with anti-ErbB-2 antibodies can specifically target ErbB-2 positive cancer cells, thereby enhancing the delivery and efficacy of peptide vaccines [<xref rid="B216-vaccines-12-00950" ref-type="bibr">216</xref>]. A recent study demonstrated that a liposome-based cancer vaccine containing ErbB-2 peptide and ovalbumin peptide OVA323-339 generated a rapid and high-titer anti-ErbB-2 antibody response in mice, increasing specific humoral immune responses by 7.3-fold in just 7 days [<xref rid="B216-vaccines-12-00950" ref-type="bibr">216</xref>]. This targeted approach reduced viable ErbB-2 overexpressing tumor cells in vitro by 96%, highlighting the potential of this delivery strategy to induce tumor cell death [<xref rid="B216-vaccines-12-00950" ref-type="bibr">216</xref>]. These targeted delivery systems improve the specificity, efficiency, and therapeutic outcomes of peptide vaccines in cancer immunotherapy.</p></sec><sec id="sec9dot2-vaccines-12-00950"><title>9.2. Liposomes</title><p>Composed of lipid bilayers, liposomes can encapsulate peptides within their aqueous core or incorporate them into their lipid bilayer, shielding them from degradation and enabling controlled release [<xref rid="B217-vaccines-12-00950" ref-type="bibr">217</xref>]. They facilitate efficient uptake by immune cells through endocytosis or membrane fusion, and their surface can be modified with ligands or antibodies for targeted delivery [<xref rid="B217-vaccines-12-00950" ref-type="bibr">217</xref>]. Liposomes also act as adjuvants, boosting the immunogenicity of the encapsulated peptides [<xref rid="B218-vaccines-12-00950" ref-type="bibr">218</xref>]. These systems have shown promising results in clinical applications, such as combining LNP-based vaccines with peptide-based cancer vaccines to further enhance antitumor efficacy [<xref rid="B212-vaccines-12-00950" ref-type="bibr">212</xref>,<xref rid="B218-vaccines-12-00950" ref-type="bibr">218</xref>]. In 2015, Boks et al. demonstrated that liposomes containing the melanoma-associated antigen glycoprotein 100280-288 peptide and the TLR4 ligand monophosphoryl lipid A (MPLA) significantly enhance antigen-specific T-cell responses by dermal DCs through improved antigen presentation [<xref rid="B219-vaccines-12-00950" ref-type="bibr">219</xref>]. Their study using a human skin explant model showed that MPLA-modified liposomes were efficiently taken up by CD1a(+) and CD14(+) dermal DCs, resulting in a higher induction of CD8(+) T-cell responses compared to non-modified liposomes or soluble MPLA [<xref rid="B219-vaccines-12-00950" ref-type="bibr">219</xref>]. Recently, Mohamad-Gabriel Alameh et al. demonstrated that lipid nanoparticles (LNPs) enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses [<xref rid="B105-vaccines-12-00950" ref-type="bibr">105</xref>]. Their study found that LNPs promote the induction of strong T follicular helper cell, germinal center B-cell, long-lived plasma cell, and memory B-cell responses, resulting in durable and protective antibodies in mice [<xref rid="B105-vaccines-12-00950" ref-type="bibr">105</xref>]. The success of these experiments has brought confidence to the development of liposomes&#8217; targeted delivery systems for peptide-based cancer vaccines.</p></sec><sec id="sec9dot3-vaccines-12-00950"><title>9.3. Polymeric Micelle</title><p>Polymeric micelle-based delivery systems are pivotal in enhancing the efficacy of peptide tumor vaccines by encapsulating hydrophobic peptides within their hydrophobic core, thereby improving stability, bioavailability, and targeted delivery [<xref rid="B212-vaccines-12-00950" ref-type="bibr">212</xref>]. These nanosized colloidal particles, formed by the self-assembly of amphiphilic block copolymers, feature a hydrophobic core and a hydrophilic shell, which protects peptides from degradation and enhances their solubility and circulation time [<xref rid="B212-vaccines-12-00950" ref-type="bibr">212</xref>,<xref rid="B220-vaccines-12-00950" ref-type="bibr">220</xref>]. Polymeric micelles, composed of biocompatible and biodegradable materials, offer improved stability, targeting, and versatility, making them a promising strategy for cancer vaccines [<xref rid="B221-vaccines-12-00950" ref-type="bibr">221</xref>]. Despite challenges in optimizing formulations, targeting efficiency, and scalability, polymeric micelles have shown significant potential in clinical applications, demonstrating enhanced delivery and immune responses in preclinical studies [<xref rid="B221-vaccines-12-00950" ref-type="bibr">221</xref>,<xref rid="B222-vaccines-12-00950" ref-type="bibr">222</xref>]. Recently, a well-defined, self-assembling mannosylated polymer has been developed for anticancer peptide antigen delivery, enhancing stability and cellular uptake [<xref rid="B222-vaccines-12-00950" ref-type="bibr">222</xref>]. This polymer&#8211;peptide conjugate forms sub-100 nm micelles at physiological pH, improves dendritic cell activation, and enhances antigen-specific T-cell responses, leading to higher antitumor immunity in tumor-bearing mice compared to a free peptide antigen [<xref rid="B222-vaccines-12-00950" ref-type="bibr">222</xref>]. Meanwhile, a mannosylated polymer called Man-VIPER, designed for peptide antigen delivery with endosomal release properties, has demonstrated superior efficacy in generating antigen-specific cytotoxic T cells and enhanced antitumor immunity in vivo, highlighting its potential as a powerful platform for cancer immunotherapy [<xref rid="B223-vaccines-12-00950" ref-type="bibr">223</xref>]. Ongoing research and development in this field will significantly advance cancer treatment and the creation of effective peptide vaccines.</p></sec><sec id="sec9dot4-vaccines-12-00950"><title>9.4. AuNP</title><p>AuNP, which range from 5 to 100 nm, have shown significant potential in peptide vaccines due to their inertness in biological environments and their ability to be precisely controlled and modified for specific uses [<xref rid="B224-vaccines-12-00950" ref-type="bibr">224</xref>]. AuNPs can be readily taken up by APCs, leading to robust CTL responses [<xref rid="B225-vaccines-12-00950" ref-type="bibr">225</xref>,<xref rid="B226-vaccines-12-00950" ref-type="bibr">226</xref>]. Specifically, a recent study demonstrated that AuNPs affected APCs differently in their responses to subsequent stimulations, including the altered secretion of cytokines and chemokines and enhanced antigen presentation by DCs, leading to stronger Th1, Th2, and Th17 responses [<xref rid="B225-vaccines-12-00950" ref-type="bibr">225</xref>]. Clinical applications have shown promising results, with AuNP-conjugated peptides inducing robust immune responses [<xref rid="B224-vaccines-12-00950" ref-type="bibr">224</xref>]. AuNPs have shown promise in cancer immunotherapy by effectively delivering peptide vaccines and enhancing antigen-specific immune responses [<xref rid="B227-vaccines-12-00950" ref-type="bibr">227</xref>]. In vivo studies demonstrated that AuNP delivery of the OVA peptide, with or without the CpG adjuvant, induced strong anti-tumor activity and prolonged survival in both prophylactic and therapeutic tumor models, highlighting their potential as effective peptide vaccine carriers [<xref rid="B227-vaccines-12-00950" ref-type="bibr">227</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec10-vaccines-12-00950"><title>10. Conclusions</title><p>Peptide-based cancer vaccines represent a promising approach in cancer immunotherapy. When combined with other immunotherapies, targeted therapies, and chemoradiotherapy, these vaccines hold significant potential to revolutionize cancer treatment. However, the absence of FDA-approved peptide-based cancer vaccines highlights the need to overcome challenges such as tumor immune escape and loss of antigen expression. To enhance efficacy, it is crucial to identify and optimize highly immunogenic epitopes and develop appropriate adjuvants and targeted delivery systems. These strategies are poised to improve patient outcomes and offer more effective and personalized cancer therapies.</p></sec></body><back><ack><title>Acknowledgments</title><p>We extend our gratitude to <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biorender.com">https://www.biorender.com</uri>, accessed on 1 June 2024, for providing drawing support.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>X.C. provided the theme and conceived the manuscript&#8217;s structure. D.L. and L.L. participated in the initial research and wrote the first draft. G.W. was responsible for the critical review and commentary. X.L. and S.W. were responsible for the visualization of the article content and the manuscript&#8217;s revision. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding authors.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><glossary><title>Glossary</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AFP</td><td align="left" valign="middle" rowspan="1" colspan="1">Alpha-fetoprotein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AML</td><td align="left" valign="middle" rowspan="1" colspan="1">Acute myeloid leukemia</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">APCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Antigen-presenting cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AuNP</td><td align="left" valign="middle" rowspan="1" colspan="1">Gold nanoparticle</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CEA</td><td align="left" valign="middle" rowspan="1" colspan="1">Carcinoembryonic antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CPA</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclophosphamide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRT</td><td align="left" valign="middle" rowspan="1" colspan="1">Chemoradiation therapy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRS</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytokine release syndrome</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTLA-4</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytotoxic T-lymphocyte-associated protein 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTLs</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytotoxic T lymphocytes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Dendritic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGFRvIII</td><td align="left" valign="middle" rowspan="1" colspan="1">Epidermal growth factor receptor variant III</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ESCC</td><td align="left" valign="middle" rowspan="1" colspan="1">Esophageal squamous cell carcinoma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GM-CSF</td><td align="left" valign="middle" rowspan="1" colspan="1">Granulocyte-macrophage colony-stimulating factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HER2</td><td align="left" valign="middle" rowspan="1" colspan="1">Human epidermal growth factor receptor 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCC</td><td align="left" valign="middle" rowspan="1" colspan="1">Hepatocellular carcinoma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HLA </td><td align="left" valign="middle" rowspan="1" colspan="1">Human leukocyte antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HPV</td><td align="left" valign="middle" rowspan="1" colspan="1">Human papillomavirus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IFA</td><td align="left" valign="middle" rowspan="1" colspan="1">Incomplete Freund&#8217;s adjuvant</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IFN</td><td align="left" valign="middle" rowspan="1" colspan="1">Interferon</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IDH1</td><td align="left" valign="middle" rowspan="1" colspan="1">Isocitrate dehydrogenase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KRAS</td><td align="left" valign="middle" rowspan="1" colspan="1">Kirsten rat sarcoma viral oncogene homolog</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LNPs</td><td align="left" valign="middle" rowspan="1" colspan="1">Lipid nanoparticles</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LPS</td><td align="left" valign="middle" rowspan="1" colspan="1">Lipopolysaccharide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAGE</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma antigen gene</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Myeloid-derived suppressor cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MHC</td><td align="left" valign="middle" rowspan="1" colspan="1">Major histocompatibility complex</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MPLA</td><td align="left" valign="middle" rowspan="1" colspan="1">Monophosphoryl lipid A</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-small-cell lung cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NY-ESO-1</td><td align="left" valign="middle" rowspan="1" colspan="1">New York esophageal squamous cell carcinoma 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ODNs</td><td align="left" valign="middle" rowspan="1" colspan="1">Oligodeoxynucleotides</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OS</td><td align="left" valign="middle" rowspan="1" colspan="1">Overall survival</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OVA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ovalbumin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PFS</td><td align="left" valign="middle" rowspan="1" colspan="1">Progression-free survival</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Programmed cell death protein 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD-L1</td><td align="left" valign="middle" rowspan="1" colspan="1">Programmed death-ligand 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PPV</td><td align="left" valign="middle" rowspan="1" colspan="1">Personalized peptide vaccination</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PSA</td><td align="left" valign="middle" rowspan="1" colspan="1">Prostate-specific antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TAAs</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor-associated antigens</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCR</td><td align="left" valign="middle" rowspan="1" colspan="1">T-cell receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLR</td><td align="left" valign="middle" rowspan="1" colspan="1">Toll-like receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tregs</td><td align="left" valign="middle" rowspan="1" colspan="1">Regulatory T cells</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-vaccines-12-00950"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decker</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Safdar</surname><given-names>A.</given-names></name></person-group><article-title>Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley&#8217;s legacy revisited</article-title><source>Cytokine Growth Factor Rev.</source><year>2009</year><volume>20</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2009.07.004</pub-id><pub-id pub-id-type="pmid">19656718</pub-id></element-citation></ref><ref id="B2-vaccines-12-00950"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoption Cann</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>van Netten</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>van Netten</surname><given-names>C.</given-names></name></person-group><article-title>Dr William Coley and tumour regression: A place in history or in the future</article-title><source>Postgrad. Med. J.</source><year>2003</year><volume>79</volume><fpage>672</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1093/postgradmedj/79.938.672</pub-id><pub-id pub-id-type="pmid">14707241</pub-id><pub-id pub-id-type="pmcid">PMC1742910</pub-id></element-citation></ref><ref id="B3-vaccines-12-00950"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coley</surname><given-names>W.B.</given-names></name></person-group><article-title>The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the <italic toggle="yes">Bacillus prodigiosus</italic>)</article-title><source>Proc. R. Soc. Med.</source><year>1910</year><volume>3</volume><fpage>1</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1177/003591571000301601</pub-id><pub-id pub-id-type="pmid">19974799</pub-id><pub-id pub-id-type="pmcid">PMC1961042</pub-id></element-citation></ref><ref id="B4-vaccines-12-00950"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Bruggen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Traversari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chomez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lurquin</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Plaen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van den Eynde</surname><given-names>B.</given-names></name><name name-style="western"><surname>Knuth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boon</surname><given-names>T.</given-names></name></person-group><article-title>A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma</article-title><source>Science</source><year>1991</year><volume>254</volume><fpage>1643</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1126/science.1840703</pub-id><pub-id pub-id-type="pmid">1840703</pub-id></element-citation></ref><ref id="B5-vaccines-12-00950"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L.J.</given-names></name></person-group><article-title>Cancer Tumor antigens</article-title><source>Curr. Opin. Immunol.</source><year>1997</year><volume>9</volume><fpage>681</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(97)80049-0</pub-id><pub-id pub-id-type="pmid">9438857</pub-id></element-citation></ref><ref id="B6-vaccines-12-00950"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burnet</surname><given-names>F.M.</given-names></name></person-group><article-title>The concept of immunological surveillance</article-title><source>Prog. Exp. Tumor Res.</source><year>1970</year><volume>13</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1159/000386035</pub-id><pub-id pub-id-type="pmid">4921480</pub-id></element-citation></ref><ref id="B7-vaccines-12-00950"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>L.</given-names></name></person-group><article-title>On immunosurveillance in human cancer</article-title><source>Yale J. Biol. Med.</source><year>1982</year><volume>55</volume><fpage>329</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">6758376</pub-id><pub-id pub-id-type="pmcid">PMC2596448</pub-id></element-citation></ref><ref id="B8-vaccines-12-00950"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name></person-group><article-title>Elements of cancer immunity and the cancer-immune set point</article-title><source>Nature</source><year>2017</year><volume>541</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/nature21349</pub-id><pub-id pub-id-type="pmid">28102259</pub-id></element-citation></ref><ref id="B9-vaccines-12-00950"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Peptide-based therapeutic cancer vaccine: Current trends in clinical application</article-title><source>Cell Prolif.</source><year>2021</year><volume>54</volume><fpage>e13025</fpage><pub-id pub-id-type="doi">10.1111/cpr.13025</pub-id><pub-id pub-id-type="pmid">33754407</pub-id><pub-id pub-id-type="pmcid">PMC8088465</pub-id></element-citation></ref><ref id="B10-vaccines-12-00950"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melief</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>van Hall</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arens</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>S.H.</given-names></name></person-group><article-title>Therapeutic cancer vaccines</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>3401</fpage><lpage>3412</lpage><pub-id pub-id-type="doi">10.1172/JCI80009</pub-id><pub-id pub-id-type="pmid">26214521</pub-id><pub-id pub-id-type="pmcid">PMC4588240</pub-id></element-citation></ref><ref id="B11-vaccines-12-00950"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butterfield</surname><given-names>L.H.</given-names></name></person-group><article-title>Cancer vaccines</article-title><source>BMJ</source><year>2015</year><volume>350</volume><fpage>h988</fpage><pub-id pub-id-type="doi">10.1136/bmj.h988</pub-id><pub-id pub-id-type="pmid">25904595</pub-id><pub-id pub-id-type="pmcid">PMC4707521</pub-id></element-citation></ref><ref id="B12-vaccines-12-00950"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palucka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name></person-group><article-title>Dendritic-cell-based therapeutic cancer vaccines</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.004</pub-id><pub-id pub-id-type="pmid">23890062</pub-id><pub-id pub-id-type="pmcid">PMC3788678</pub-id></element-citation></ref><ref id="B13-vaccines-12-00950"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Sporn</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kurtzman</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ergin</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Mukherji</surname><given-names>B.</given-names></name></person-group><article-title>Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine</article-title><source>Cancer Res.</source><year>1996</year><volume>56</volume><fpage>2479</fpage><lpage>2483</lpage><pub-id pub-id-type="pmid">8653680</pub-id></element-citation></ref><ref id="B14-vaccines-12-00950"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeurer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Storkus</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Kirkwood</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lotze</surname><given-names>M.T.</given-names></name></person-group><article-title>New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines</article-title><source>Melanoma Res.</source><year>1996</year><volume>6</volume><fpage>11</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1097/00008390-199602000-00003</pub-id><pub-id pub-id-type="pmid">8640065</pub-id></element-citation></ref><ref id="B15-vaccines-12-00950"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherji</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okino</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamase</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sporn</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kurtzman</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ergin</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Ozols</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meehan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>8078</fpage><lpage>8082</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.17.8078</pub-id><pub-id pub-id-type="pmid">7644541</pub-id><pub-id pub-id-type="pmcid">PMC41290</pub-id></element-citation></ref><ref id="B16-vaccines-12-00950"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biri-Kov&#225;cs</surname><given-names>B.</given-names></name><name name-style="western"><surname>B&#225;n&#243;czi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tummalapally</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szab&#243;</surname><given-names>I.</given-names></name></person-group><article-title>Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>452</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15020452</pub-id><pub-id pub-id-type="pmid">36839774</pub-id><pub-id pub-id-type="pmcid">PMC9963291</pub-id></element-citation></ref><ref id="B17-vaccines-12-00950"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Keskin</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bozym</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Luoma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peter</surname><given-names>L.</given-names></name><etal/></person-group><article-title>An immunogenic personal neoantigen vaccine for patients with melanoma</article-title><source>Nature</source><year>2017</year><volume>547</volume><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/nature22991</pub-id><pub-id pub-id-type="pmid">28678778</pub-id><pub-id pub-id-type="pmcid">PMC5577644</pub-id></element-citation></ref><ref id="B18-vaccines-12-00950"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmid">22437870</pub-id><pub-id pub-id-type="pmcid">PMC4856023</pub-id></element-citation></ref><ref id="B19-vaccines-12-00950"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arlen</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Gulley</surname><given-names>J.L.</given-names></name></person-group><article-title>Cancer vaccines: Moving beyond current paradigms</article-title><source>Clin. Cancer Res.</source><year>2007</year><volume>13</volume><fpage>3776</fpage><lpage>3782</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0588</pub-id><pub-id pub-id-type="pmid">17606707</pub-id><pub-id pub-id-type="pmcid">PMC2536755</pub-id></element-citation></ref><ref id="B20-vaccines-12-00950"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantoff</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Higano</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Shore</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Small</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Penson</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Redfern</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Dreicer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R.B.</given-names></name><etal/></person-group><article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>411</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1001294</pub-id><pub-id pub-id-type="pmid">20818862</pub-id></element-citation></ref><ref id="B21-vaccines-12-00950"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartzentruber</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Conry</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Treisman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gailani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Conlon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pockaj</surname><given-names>B.</given-names></name><etal/></person-group><article-title>gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>364</volume><fpage>2119</fpage><lpage>2127</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1012863</pub-id><pub-id pub-id-type="pmid">21631324</pub-id><pub-id pub-id-type="pmcid">PMC3517182</pub-id></element-citation></ref><ref id="B22-vaccines-12-00950"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoen</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Boardman</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Cruz-Correa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kastenberg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hur</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dzubinski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma</article-title><source>Clin. Cancer Res.</source><year>2023</year><volume>29</volume><fpage>1678</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-3168</pub-id><pub-id pub-id-type="pmid">36892581</pub-id><pub-id pub-id-type="pmcid">PMC10159922</pub-id></element-citation></ref><ref id="B23-vaccines-12-00950"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.D.</given-names></name></person-group><article-title>Breast Cancer Vaccines: Disappointing or Promising?</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>828386</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.828386</pub-id><pub-id pub-id-type="pmid">35154149</pub-id><pub-id pub-id-type="pmcid">PMC8831788</pub-id></element-citation></ref><ref id="B24-vaccines-12-00950"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahedipour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jamialahmadi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zamani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reza Jaafari</surname><given-names>M.</given-names></name></person-group><article-title>Improving the efficacy of peptide vaccines in cancer immunotherapy</article-title><source>Int. Immunopharmacol.</source><year>2023</year><volume>123</volume><fpage>110721</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2023.110721</pub-id><pub-id pub-id-type="pmid">37543011</pub-id></element-citation></ref><ref id="B25-vaccines-12-00950"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klausen</surname><given-names>U.</given-names></name><name name-style="western"><surname>Holmberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holmstr&#246;m</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>J&#248;rgensen</surname><given-names>N.G.D.</given-names></name><name name-style="western"><surname>Grauslund</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Svane</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>M.H.</given-names></name></person-group><article-title>Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>2264</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02264</pub-id><pub-id pub-id-type="pmid">30327655</pub-id><pub-id pub-id-type="pmcid">PMC6174926</pub-id></element-citation></ref><ref id="B26-vaccines-12-00950"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schachter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Long</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Arance</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grob</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Mortier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daud</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carlino</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lotem</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pembrolizumab versus Ipilimumab in Advanced Melanoma</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>2521</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1503093</pub-id><pub-id pub-id-type="pmid">25891173</pub-id></element-citation></ref><ref id="B27-vaccines-12-00950"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motzer</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Escudier</surname><given-names>B.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>George</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hammers</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Srinivas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tykodi</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Procopio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Plimack</surname><given-names>E.R.</given-names></name><etal/></person-group><article-title>Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>1803</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1510665</pub-id><pub-id pub-id-type="pmid">26406148</pub-id><pub-id pub-id-type="pmcid">PMC5719487</pub-id></element-citation></ref><ref id="B28-vaccines-12-00950"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brahmer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reckamp</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Baas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crin&#242;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eberhardt</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Poddubskaya</surname><given-names>E.</given-names></name><name name-style="western"><surname>Antonia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pluzanski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vokes</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Holgado</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>123</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1504627</pub-id><pub-id pub-id-type="pmid">26028407</pub-id><pub-id pub-id-type="pmcid">PMC4681400</pub-id></element-citation></ref><ref id="B29-vaccines-12-00950"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plosker</surname><given-names>G.L.</given-names></name></person-group><article-title>Sipuleucel-T: In metastatic castration-resistant prostate cancer</article-title><source>Drugs</source><year>2011</year><volume>71</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.2165/11206840-000000000-00000</pub-id><pub-id pub-id-type="pmid">21175243</pub-id></element-citation></ref><ref id="B30-vaccines-12-00950"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Vaccine adjuvants: Putting innate immunity to work</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></element-citation></ref><ref id="B31-vaccines-12-00950"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>Cancer immunotherapy: Moving beyond current vaccines</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>909</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1038/nm1100</pub-id><pub-id pub-id-type="pmid">15340416</pub-id><pub-id pub-id-type="pmcid">PMC1435696</pub-id></element-citation></ref><ref id="B32-vaccines-12-00950"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bloy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Buqu&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cremer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Saut&#232;s-Fridman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tartour</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Trial Watch: Peptide-based anticancer vaccines</article-title><source>Oncoimmunology</source><year>2015</year><volume>4</volume><fpage>e974411</fpage><pub-id pub-id-type="doi">10.4161/2162402X.2014.974411</pub-id><pub-id pub-id-type="pmid">26137405</pub-id><pub-id pub-id-type="pmcid">PMC4485775</pub-id></element-citation></ref><ref id="B33-vaccines-12-00950"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calvo Tard&#243;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dutoit</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>P.R.</given-names></name></person-group><article-title>Peptides as cancer vaccines</article-title><source>Curr. Opin. Pharmacol.</source><year>2019</year><volume>47</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2019.01.007</pub-id><pub-id pub-id-type="pmid">30831470</pub-id></element-citation></ref><ref id="B34-vaccines-12-00950"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bezu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cerrato</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fucikova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spisek</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name></person-group><article-title>Trial watch: Peptide-based vaccines in anticancer therapy</article-title><source>Oncoimmunology</source><year>2018</year><volume>7</volume><fpage>e1511506</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2018.1511506</pub-id><pub-id pub-id-type="pmid">30524907</pub-id><pub-id pub-id-type="pmcid">PMC6279318</pub-id></element-citation></ref><ref id="B35-vaccines-12-00950"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shemesh</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>B.Q.</given-names></name><name name-style="western"><surname>Rotte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Twomey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Girish</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.</given-names></name></person-group><article-title>Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities</article-title><source>Mol. Ther.</source><year>2021</year><volume>29</volume><fpage>555</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.09.038</pub-id><pub-id pub-id-type="pmid">33038322</pub-id><pub-id pub-id-type="pmcid">PMC7854282</pub-id></element-citation></ref><ref id="B36-vaccines-12-00950"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>A.</given-names></name></person-group><article-title>Personalized peptide vaccines: A new therapeutic modality for cancer</article-title><source>Cancer Sci.</source><year>2006</year><volume>97</volume><fpage>970</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2006.00272.x</pub-id><pub-id pub-id-type="pmid">16984371</pub-id><pub-id pub-id-type="pmcid">PMC11158045</pub-id></element-citation></ref><ref id="B37-vaccines-12-00950"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slingluff</surname><given-names>C.L.</given-names><suffix>Jr.</suffix></name></person-group><article-title>The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination?</article-title><source>Cancer J.</source><year>2011</year><volume>17</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e318233e5b2</pub-id><pub-id pub-id-type="pmid">21952285</pub-id><pub-id pub-id-type="pmcid">PMC3204371</pub-id></element-citation></ref><ref id="B38-vaccines-12-00950"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rammensee</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Walz</surname><given-names>J.S.</given-names></name></person-group><article-title>The Peptide Vaccine of the Future</article-title><source>Mol. Cell Proteom.</source><year>2021</year><volume>20</volume><fpage>100022</fpage><pub-id pub-id-type="doi">10.1074/mcp.R120.002309</pub-id><pub-id pub-id-type="pmcid">PMC7950068</pub-id><pub-id pub-id-type="pmid">33583769</pub-id></element-citation></ref><ref id="B39-vaccines-12-00950"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name></person-group><article-title>Peptide-based synthetic vaccines</article-title><source>Chem. Sci.</source><year>2016</year><volume>7</volume><fpage>842</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1039/C5SC03892H</pub-id><pub-id pub-id-type="pmid">28791117</pub-id><pub-id pub-id-type="pmcid">PMC5529997</pub-id></element-citation></ref><ref id="B40-vaccines-12-00950"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaczmarek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pozna&#324;ska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fechner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Michalska</surname><given-names>N.</given-names></name><name name-style="western"><surname>Paszkowska</surname><given-names>S.</given-names></name><name name-style="western"><surname>Napiera&#322;a</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mackiewicz</surname><given-names>A.</given-names></name></person-group><article-title>Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>2159</elocation-id><pub-id pub-id-type="doi">10.3390/cells12172159</pub-id><pub-id pub-id-type="pmid">37681891</pub-id><pub-id pub-id-type="pmcid">PMC10486481</pub-id></element-citation></ref><ref id="B41-vaccines-12-00950"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paston</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Brentville</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Symonds</surname><given-names>P.</given-names></name><name name-style="western"><surname>Durrant</surname><given-names>L.G.</given-names></name></person-group><article-title>Cancer Vaccines, Adjuvants, and Delivery Systems</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>627932</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.627932</pub-id><pub-id pub-id-type="pmid">33859638</pub-id><pub-id pub-id-type="pmcid">PMC8042385</pub-id></element-citation></ref><ref id="B42-vaccines-12-00950"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Overwijk</surname><given-names>W.W.</given-names></name></person-group><article-title>Adjuvants for peptide-based cancer vaccines</article-title><source>J. Immunother. Cancer</source><year>2016</year><volume>4</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/s40425-016-0160-y</pub-id><pub-id pub-id-type="pmid">27660710</pub-id><pub-id pub-id-type="pmcid">PMC5028954</pub-id></element-citation></ref><ref id="B43-vaccines-12-00950"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Backlund</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Holden</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Garafola</surname><given-names>D.</given-names></name><name name-style="western"><surname>Farquhar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Maiorino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iorgulescu</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Reardon</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2204078119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2204078119</pub-id><pub-id pub-id-type="pmid">35914154</pub-id><pub-id pub-id-type="pmcid">PMC9371699</pub-id></element-citation></ref><ref id="B44-vaccines-12-00950"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moldaver</surname><given-names>D.</given-names></name><name name-style="western"><surname>Larch&#233;</surname><given-names>M.</given-names></name></person-group><article-title>Immunotherapy with peptides</article-title><source>Allergy</source><year>2011</year><volume>66</volume><fpage>784</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1111/j.1398-9995.2011.02610.x</pub-id><pub-id pub-id-type="pmid">21507007</pub-id></element-citation></ref><ref id="B45-vaccines-12-00950"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parmiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maccalli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parolini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Maio</surname><given-names>M.</given-names></name></person-group><article-title>Peptide-based vaccines for cancer therapy</article-title><source>Hum. Vaccin. Immunother.</source><year>2014</year><volume>10</volume><fpage>3175</fpage><lpage>3178</lpage><pub-id pub-id-type="doi">10.4161/hv.29418</pub-id><pub-id pub-id-type="pmid">25483658</pub-id><pub-id pub-id-type="pmcid">PMC4514143</pub-id></element-citation></ref><ref id="B46-vaccines-12-00950"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pavlenko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vlasov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramenskaya</surname><given-names>G.</given-names></name></person-group><article-title>Peptide-Based Therapeutics for Oncology</article-title><source>Pharmaceut. Med.</source><year>2019</year><volume>33</volume><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s40290-018-0261-7</pub-id><pub-id pub-id-type="pmid">31933267</pub-id></element-citation></ref><ref id="B47-vaccines-12-00950"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Gully</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Gras</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beringer</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Kjer-Nielsen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cebon</surname><given-names>J.</given-names></name><name name-style="western"><surname>McCluskey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rossjohn</surname><given-names>J.</given-names></name></person-group><article-title>Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>1026</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03321-w</pub-id><pub-id pub-id-type="pmid">29531227</pub-id><pub-id pub-id-type="pmcid">PMC5847591</pub-id></element-citation></ref><ref id="B48-vaccines-12-00950"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Neoantigen vaccine: An emerging tumor immunotherapy</article-title><source>Mol. Cancer</source><year>2019</year><volume>18</volume><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-1055-6</pub-id><pub-id pub-id-type="pmid">31443694</pub-id><pub-id pub-id-type="pmcid">PMC6708248</pub-id></element-citation></ref><ref id="B49-vaccines-12-00950"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abd-Aziz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Poh</surname><given-names>C.L.</given-names></name></person-group><article-title>Development of Peptide-Based Vaccines for Cancer</article-title><source>J. Oncol.</source><year>2022</year><volume>2022</volume><fpage>9749363</fpage><pub-id pub-id-type="doi">10.1155/2022/9749363</pub-id><pub-id pub-id-type="pmid">35342400</pub-id><pub-id pub-id-type="pmcid">PMC8941562</pub-id></element-citation></ref><ref id="B50-vaccines-12-00950"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Egawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>H.</given-names></name></person-group><article-title>Personalized peptide vaccines and their relation to other therapies in urological cancer</article-title><source>Nat. Rev. Urol.</source><year>2017</year><volume>14</volume><fpage>501</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2017.77</pub-id><pub-id pub-id-type="pmid">28561807</pub-id></element-citation></ref><ref id="B51-vaccines-12-00950"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nobuoka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakatsura</surname><given-names>T.</given-names></name></person-group><article-title>Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy</article-title><source>Hum. Vaccin. Immunother.</source><year>2013</year><volume>9</volume><fpage>1234</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.4161/hv.23990</pub-id><pub-id pub-id-type="pmid">23411443</pub-id><pub-id pub-id-type="pmcid">PMC3901811</pub-id></element-citation></ref><ref id="B52-vaccines-12-00950"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jhunjhunwala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Phung</surname><given-names>Q.T.</given-names></name><name name-style="western"><surname>Lupardus</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tanguay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bumbaca</surname><given-names>S.</given-names></name><name name-style="western"><surname>Franci</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Fritsche</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weinschenk</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>572</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1038/nature14001</pub-id><pub-id pub-id-type="pmid">25428506</pub-id></element-citation></ref><ref id="B53-vaccines-12-00950"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bassani-Sternberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Br&#228;unlein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Klar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Engleitner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sinitcyn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Audehm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Straub</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Slotta-Huspenina</surname><given-names>J.</given-names></name><name name-style="western"><surname>Specht</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13404</fpage><pub-id pub-id-type="doi">10.1038/ncomms13404</pub-id><pub-id pub-id-type="pmid">27869121</pub-id><pub-id pub-id-type="pmcid">PMC5121339</pub-id></element-citation></ref><ref id="B54-vaccines-12-00950"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segal</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Peggs</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Velculescu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kinzler</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Vogelstein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name></person-group><article-title>Epitope landscape in breast and colorectal cancer</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>889</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-3095</pub-id><pub-id pub-id-type="pmid">18245491</pub-id></element-citation></ref><ref id="B55-vaccines-12-00950"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajasagi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Fritsch</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Keskin</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>DeLuca</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carmona</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sougnez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cibulskis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia</article-title><source>Blood</source><year>2014</year><volume>124</volume><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-04-567933</pub-id><pub-id pub-id-type="pmid">24891321</pub-id><pub-id pub-id-type="pmcid">PMC4102716</pub-id></element-citation></ref><ref id="B56-vaccines-12-00950"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finn</surname><given-names>O.J.</given-names></name></person-group><article-title>Cancer immunology</article-title><source>N. Engl. J. Med.</source><year>2008</year><volume>358</volume><fpage>2704</fpage><lpage>2715</lpage><pub-id pub-id-type="doi">10.1056/NEJMra072739</pub-id><pub-id pub-id-type="pmid">18565863</pub-id></element-citation></ref><ref id="B57-vaccines-12-00950"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scanlan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L.J.</given-names></name></person-group><article-title>The cancer/testis genes: Review, standardization, and commentary</article-title><source>Cancer Immun.</source><year>2004</year><volume>4</volume><fpage>1</fpage><pub-id pub-id-type="pmid">14738373</pub-id></element-citation></ref><ref id="B58-vaccines-12-00950"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schumacher</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name></person-group><article-title>Neoantigens in cancer immunotherapy</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id><pub-id pub-id-type="pmid">25838375</pub-id></element-citation></ref><ref id="B59-vaccines-12-00950"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizvi</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kvistborg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Havel</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>T.S.</given-names></name><etal/></person-group><article-title>Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>124</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1348</pub-id><pub-id pub-id-type="pmid">25765070</pub-id><pub-id pub-id-type="pmcid">PMC4993154</pub-id></element-citation></ref><ref id="B60-vaccines-12-00950"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoof</surname><given-names>I.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>O.</given-names></name><name name-style="western"><surname>Buus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>M.</given-names></name></person-group><article-title>NetMHCpan, a method for MHC class I binding prediction beyond humans</article-title><source>Immunogenetics</source><year>2009</year><volume>61</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s00251-008-0341-z</pub-id><pub-id pub-id-type="pmid">19002680</pub-id><pub-id pub-id-type="pmcid">PMC3319061</pub-id></element-citation></ref><ref id="B61-vaccines-12-00950"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tenzer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bulik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schoor</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lemmel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schatz</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Kloetzel</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Rammensee</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Schild</surname><given-names>H.</given-names></name><name name-style="western"><surname>Holzh&#252;tter</surname><given-names>H.G.</given-names></name></person-group><article-title>Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding</article-title><source>Cell Mol. Life Sci.</source><year>2005</year><volume>62</volume><fpage>1025</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1007/s00018-005-4528-2</pub-id><pub-id pub-id-type="pmid">15868101</pub-id><pub-id pub-id-type="pmcid">PMC11924537</pub-id></element-citation></ref><ref id="B62-vaccines-12-00950"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andreatta</surname><given-names>M.</given-names></name></person-group><article-title>NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets</article-title><source>Genome Med.</source><year>2016</year><volume>8</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s13073-016-0288-x</pub-id><pub-id pub-id-type="pmid">27029192</pub-id><pub-id pub-id-type="pmcid">PMC4812631</pub-id></element-citation></ref><ref id="B63-vaccines-12-00950"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jespersen</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marcatili</surname><given-names>P.</given-names></name></person-group><article-title>BepiPred-2.0: Improving sequence-based B-cell epitope prediction using conformational epitopes</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>W24</fpage><lpage>W29</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx346</pub-id><pub-id pub-id-type="pmid">28472356</pub-id><pub-id pub-id-type="pmcid">PMC5570230</pub-id></element-citation></ref><ref id="B64-vaccines-12-00950"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gubin</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>H.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hundal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arthur</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Krebber</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1038/nature13988</pub-id><pub-id pub-id-type="pmid">25428507</pub-id><pub-id pub-id-type="pmcid">PMC4279952</pub-id></element-citation></ref><ref id="B65-vaccines-12-00950"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreiter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vormehr</surname><given-names>M.</given-names></name><name name-style="western"><surname>van de Roemer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#246;wer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diekmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boegel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schr&#246;rs</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vascotto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castle</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Mutant MHC class II epitopes drive therapeutic immune responses to cancer</article-title><source>Nature</source><year>2015</year><volume>520</volume><fpage>692</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1038/nature14426</pub-id><pub-id pub-id-type="pmid">25901682</pub-id><pub-id pub-id-type="pmcid">PMC4838069</pub-id></element-citation></ref><ref id="B66-vaccines-12-00950"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robbins</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>El-Gamil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gartner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Teer</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Cliften</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tycksen</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1038/nm.3161</pub-id><pub-id pub-id-type="pmid">23644516</pub-id><pub-id pub-id-type="pmcid">PMC3757932</pub-id></element-citation></ref><ref id="B67-vaccines-12-00950"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vita</surname><given-names>R.</given-names></name><name name-style="western"><surname>Overton</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ponomarenko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Cantrell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Gabbard</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Hix</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The immune epitope database (IEDB) 3.0</article-title><source>Nucleic Acids Res.</source><year>2015</year><volume>43</volume><fpage>D405</fpage><lpage>D412</lpage><pub-id pub-id-type="doi">10.1093/nar/gku938</pub-id><pub-id pub-id-type="pmid">25300482</pub-id><pub-id pub-id-type="pmcid">PMC4384014</pub-id></element-citation></ref><ref id="B68-vaccines-12-00950"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleri</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Salimi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vita</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name></person-group><article-title>The Immune Epitope Database: How Data Are Entered and Retrieved</article-title><source>J. Immunol. Res.</source><year>2017</year><volume>2017</volume><fpage>5974574</fpage><pub-id pub-id-type="doi">10.1155/2017/5974574</pub-id><pub-id pub-id-type="pmid">28634590</pub-id><pub-id pub-id-type="pmcid">PMC5467323</pub-id></element-citation></ref><ref id="B69-vaccines-12-00950"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keskin</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Anandappa</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tirosh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mathewson</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>G.</given-names></name><name name-style="western"><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Felt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gjini</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial</article-title><source>Nature</source><year>2019</year><volume>565</volume><fpage>234</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0792-9</pub-id><pub-id pub-id-type="pmid">30568305</pub-id><pub-id pub-id-type="pmcid">PMC6546179</pub-id></element-citation></ref><ref id="B70-vaccines-12-00950"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rimawi</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>R.</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>C.K.</given-names></name></person-group><article-title>Targeting HER2 for the treatment of breast cancer</article-title><source>Annu. Rev. Med.</source><year>2015</year><volume>66</volume><fpage>111</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-042513-015127</pub-id><pub-id pub-id-type="pmid">25587647</pub-id></element-citation></ref><ref id="B71-vaccines-12-00950"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gianni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krop</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Welslau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baselga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pegram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Di&#233;ras</surname><given-names>V.</given-names></name><name name-style="western"><surname>Guardino</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Trastuzumab emtansine for HER2-positive advanced breast cancer</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>367</volume><fpage>1783</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1209124</pub-id><pub-id pub-id-type="pmid">23020162</pub-id><pub-id pub-id-type="pmcid">PMC5125250</pub-id></element-citation></ref><ref id="B72-vaccines-12-00950"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Valmori</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pittet</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Zippelius</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rimoldi</surname><given-names>D.</given-names></name><name name-style="western"><surname>L&#233;vy</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dutoit</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ayyoub</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rubio-Godoy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma</article-title><source>Immunol. Rev.</source><year>2002</year><volume>188</volume><fpage>81</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1034/j.1600-065X.2002.18808.x</pub-id><pub-id pub-id-type="pmid">12445283</pub-id></element-citation></ref><ref id="B73-vaccines-12-00950"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khammari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Labarri&#232;re</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vignard</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pandolfino</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Knol</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Qu&#233;reux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Saiagh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brocard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jotereau</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones</article-title><source>J. Investig. Dermatol.</source><year>2009</year><volume>129</volume><fpage>2835</fpage><lpage>2842</lpage><pub-id pub-id-type="doi">10.1038/jid.2009.144</pub-id><pub-id pub-id-type="pmid">19554023</pub-id></element-citation></ref><ref id="B74-vaccines-12-00950"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004035</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-004035</pub-id><pub-id pub-id-type="pmid">35338087</pub-id><pub-id pub-id-type="pmcid">PMC8961179</pub-id></element-citation></ref><ref id="B75-vaccines-12-00950"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kakinoki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Akagi</surname><given-names>M.</given-names></name></person-group><article-title>Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma</article-title><source>Eur. J. Histochem.</source><year>2022</year><volume>66</volume><fpage>3377</fpage><pub-id pub-id-type="doi">10.4081/ejh.2022.3377</pub-id><pub-id pub-id-type="pmid">35448937</pub-id><pub-id pub-id-type="pmcid">PMC9046686</pub-id></element-citation></ref><ref id="B76-vaccines-12-00950"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freiberger</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Holzmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morand</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>H&#252;llner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levesque</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koelzer</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Rupp</surname><given-names>N.J.</given-names></name></person-group><article-title>Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2023</year><volume>149</volume><fpage>5645</fpage><lpage>5653</lpage><pub-id pub-id-type="doi">10.1007/s00432-022-04514-z</pub-id><pub-id pub-id-type="pmid">36527482</pub-id><pub-id pub-id-type="pmcid">PMC10356647</pub-id></element-citation></ref><ref id="B77-vaccines-12-00950"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turriziani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fantini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benvenuto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Izzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Masuelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sacchetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Modesti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bei</surname><given-names>R.</given-names></name></person-group><article-title>Carcinoembryonic antigen (CEA)-based cancer vaccines: Recent patents and antitumor effects from experimental models to clinical trials</article-title><source>Recent. Pat. Anticancer Drug Discov.</source><year>2012</year><volume>7</volume><fpage>265</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.2174/157489212801820020</pub-id><pub-id pub-id-type="pmid">22630596</pub-id></element-citation></ref><ref id="B78-vaccines-12-00950"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zbar</surname><given-names>A.P.</given-names></name></person-group><article-title>The immunology of colorectal cancer</article-title><source>Surg. Oncol.</source><year>2004</year><volume>13</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.suronc.2004.09.010</pub-id><pub-id pub-id-type="pmid">15572086</pub-id></element-citation></ref><ref id="B79-vaccines-12-00950"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manzo-Merino</surname><given-names>J.</given-names></name><name name-style="western"><surname>Del-Toro-Arreola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rocha-Zavaleta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peralta-Zaragoza</surname><given-names>&#211;.</given-names></name><name name-style="western"><surname>Jim&#233;nez-Lima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Madrid-Marina</surname><given-names>V.</given-names></name></person-group><article-title>Immunology of cervical cancer</article-title><source>Rev. Investig. Clin.</source><year>2020</year><volume>72</volume><fpage>188</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.24875/RIC.20000057</pub-id><pub-id pub-id-type="pmid">33064686</pub-id></element-citation></ref><ref id="B80-vaccines-12-00950"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Woodhouse</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>G.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marx</surname><given-names>K.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salatino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Partridge</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nicastri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Novel canonical and non-canonical viral antigens extend current targets for immunotherapy of HPV-driven cervical cancer</article-title><source>iScience</source><year>2023</year><volume>26</volume><fpage>106101</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2023.106101</pub-id><pub-id pub-id-type="pmid">36876126</pub-id><pub-id pub-id-type="pmcid">PMC9978627</pub-id></element-citation></ref><ref id="B81-vaccines-12-00950"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mbuya</surname><given-names>W.</given-names></name><name name-style="western"><surname>Held</surname><given-names>K.</given-names></name><name name-style="western"><surname>McHaro</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Haule</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mhizde</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mnkai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahenge</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mwakatima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sembo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mwalongo</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living with HIV</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>742861</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.742861</pub-id><pub-id pub-id-type="pmid">34759925</pub-id><pub-id pub-id-type="pmcid">PMC8573218</pub-id></element-citation></ref><ref id="B82-vaccines-12-00950"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poole</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karuppiah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hartt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haidar</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Moureau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dobrzycki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Therapeutic high affinity T cell receptor targeting a KRAS(G12D) cancer neoantigen</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>5333</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32811-1</pub-id><pub-id pub-id-type="pmid">36088370</pub-id><pub-id pub-id-type="pmcid">PMC9464187</pub-id></element-citation></ref><ref id="B83-vaccines-12-00950"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leidner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sanjuan Silva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sprott</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>A.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>2112</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2119662</pub-id><pub-id pub-id-type="pmid">35648703</pub-id><pub-id pub-id-type="pmcid">PMC9531755</pub-id></element-citation></ref><ref id="B84-vaccines-12-00950"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hanada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.C.</given-names></name></person-group><article-title>Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors</article-title><source>Cancer Immunol. Res.</source><year>2016</year><volume>4</volume><fpage>204</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-15-0188</pub-id><pub-id pub-id-type="pmid">26701267</pub-id><pub-id pub-id-type="pmcid">PMC4775432</pub-id></element-citation></ref><ref id="B85-vaccines-12-00950"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Platten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bunse</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wick</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bunse</surname><given-names>T.</given-names></name><name name-style="western"><surname>Le Cornet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Harting</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sahm</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sanghvi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Poschke</surname><given-names>I.</given-names></name><etal/></person-group><article-title>A vaccine targeting mutant IDH1 in newly diagnosed glioma</article-title><source>Nature</source><year>2021</year><volume>592</volume><fpage>463</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03363-z</pub-id><pub-id pub-id-type="pmid">33762734</pub-id><pub-id pub-id-type="pmcid">PMC8046668</pub-id></element-citation></ref><ref id="B86-vaccines-12-00950"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabit</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Furuta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hamada</surname><given-names>J.</given-names></name></person-group><article-title>Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence</article-title><source>Brain Tumor Pathol.</source><year>2014</year><volume>31</volume><fpage>242</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/s10014-013-0172-y</pub-id><pub-id pub-id-type="pmid">24384677</pub-id></element-citation></ref><ref id="B87-vaccines-12-00950"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fields</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Noble</surname><given-names>R.L.</given-names></name></person-group><article-title>Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids</article-title><source>Int. J. Pept. Protein Res.</source><year>1990</year><volume>35</volume><fpage>161</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3011.1990.tb00939.x</pub-id><pub-id pub-id-type="pmid">2191922</pub-id></element-citation></ref><ref id="B88-vaccines-12-00950"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aebersold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>M.</given-names></name></person-group><article-title>Mass spectrometry-based proteomics</article-title><source>Nature</source><year>2003</year><volume>422</volume><fpage>198</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1038/nature01511</pub-id><pub-id pub-id-type="pmid">12634793</pub-id></element-citation></ref><ref id="B89-vaccines-12-00950"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>B.</given-names></name></person-group><article-title>The perfect mix: Recent progress in adjuvant research</article-title><source>Nat. Rev. Microbiol.</source><year>2007</year><volume>5</volume><fpage>505</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1681</pub-id><pub-id pub-id-type="pmid">17558426</pub-id></element-citation></ref><ref id="B90-vaccines-12-00950"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>G.T.</given-names></name></person-group><article-title>Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns</article-title><source>Nat. Rev. Immunol.</source><year>2010</year><volume>10</volume><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1038/nri2868</pub-id><pub-id pub-id-type="pmid">20948547</pub-id></element-citation></ref><ref id="B91-vaccines-12-00950"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>J.A.</given-names></name></person-group><article-title>Targeting dendritic cells with biomaterials: Developing the next generation of vaccines</article-title><source>Trends Immunol.</source><year>2006</year><volume>27</volume><fpage>573</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/j.it.2006.10.005</pub-id><pub-id pub-id-type="pmid">17049307</pub-id></element-citation></ref><ref id="B92-vaccines-12-00950"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Titball</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D.</given-names></name></person-group><article-title>Vaccine delivery using nanoparticles</article-title><source>Front. Cell Infect. Microbiol.</source><year>2013</year><volume>3</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2013.00013</pub-id><pub-id pub-id-type="pmid">23532930</pub-id><pub-id pub-id-type="pmcid">PMC3607064</pub-id></element-citation></ref><ref id="B93-vaccines-12-00950"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janeway</surname><given-names>C.A.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Innate immune recognition</article-title><source>Annu. Rev. Immunol.</source><year>2002</year><volume>20</volume><fpage>197</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.20.083001.084359</pub-id><pub-id pub-id-type="pmid">11861602</pub-id></element-citation></ref><ref id="B94-vaccines-12-00950"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodcock</surname><given-names>J.</given-names></name><name name-style="western"><surname>Woosley</surname><given-names>R.</given-names></name></person-group><article-title>The FDA critical path initiative and its influence on new drug development</article-title><source>Annu. Rev. Med.</source><year>2008</year><volume>59</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.59.090506.155819</pub-id><pub-id pub-id-type="pmid">18186700</pub-id></element-citation></ref><ref id="B95-vaccines-12-00950"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaitin</surname><given-names>K.I.</given-names></name></person-group><article-title>Deconstructing the drug development process: The new face of innovation</article-title><source>Clin. Pharmacol. Ther.</source><year>2010</year><volume>87</volume><fpage>356</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1038/clpt.2009.293</pub-id><pub-id pub-id-type="pmid">20130565</pub-id><pub-id pub-id-type="pmcid">PMC2953249</pub-id></element-citation></ref><ref id="B96-vaccines-12-00950"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>R.M.</given-names></name></person-group><article-title>Dendritic cells and the control of immunity</article-title><source>Nature</source><year>1998</year><volume>392</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/32588</pub-id><pub-id pub-id-type="pmid">9521319</pub-id></element-citation></ref><ref id="B97-vaccines-12-00950"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sallusto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name></person-group><article-title>Origin, maturation and antigen presenting function of dendritic cells</article-title><source>Curr. Opin. Immunol.</source><year>1997</year><volume>9</volume><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(97)80153-7</pub-id><pub-id pub-id-type="pmid">9039784</pub-id></element-citation></ref><ref id="B98-vaccines-12-00950"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Wearsch</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P.</given-names></name></person-group><article-title>Pathways of antigen processing</article-title><source>Annu. Rev. Immunol.</source><year>2013</year><volume>31</volume><fpage>443</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095910</pub-id><pub-id pub-id-type="pmid">23298205</pub-id><pub-id pub-id-type="pmcid">PMC4026165</pub-id></element-citation></ref><ref id="B99-vaccines-12-00950"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joffre</surname><given-names>O.P.</given-names></name><name name-style="western"><surname>Segura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Savina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Amigorena</surname><given-names>S.</given-names></name></person-group><article-title>Cross-presentation by dendritic cells</article-title><source>Nat. Rev. Immunol.</source><year>2012</year><volume>12</volume><fpage>557</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/nri3254</pub-id><pub-id pub-id-type="pmid">22790179</pub-id></element-citation></ref><ref id="B100-vaccines-12-00950"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neefjes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jongsma</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bakke</surname><given-names>O.</given-names></name></person-group><article-title>Towards a systems understanding of MHC class I and MHC class II antigen presentation</article-title><source>Nat. Rev. Immunol.</source><year>2011</year><volume>11</volume><fpage>823</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1038/nri3084</pub-id><pub-id pub-id-type="pmid">22076556</pub-id></element-citation></ref><ref id="B101-vaccines-12-00950"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>R.M.</given-names></name></person-group><article-title>Dendritic cells: Specialized and regulated antigen processing machines</article-title><source>Cell</source><year>2001</year><volume>106</volume><fpage>255</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00449-4</pub-id><pub-id pub-id-type="pmid">11509172</pub-id></element-citation></ref><ref id="B102-vaccines-12-00950"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Teyton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>I.A.</given-names></name></person-group><article-title>Structural basis of T cell recognition</article-title><source>Annu. Rev. Immunol.</source><year>1999</year><volume>17</volume><fpage>369</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.17.1.369</pub-id><pub-id pub-id-type="pmid">10358763</pub-id></element-citation></ref><ref id="B103-vaccines-12-00950"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Flies</surname><given-names>D.B.</given-names></name></person-group><article-title>Molecular mechanisms of T cell co-stimulation and co-inhibition</article-title><source>Nat. Rev. Immunol.</source><year>2013</year><volume>13</volume><fpage>227</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/nri3405</pub-id><pub-id pub-id-type="pmid">23470321</pub-id><pub-id pub-id-type="pmcid">PMC3786574</pub-id></element-citation></ref><ref id="B104-vaccines-12-00950"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Radvanyi</surname><given-names>L.G.</given-names></name></person-group><article-title>Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer</article-title><source>BioDrugs</source><year>2015</year><volume>29</volume><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s40259-014-0114-1</pub-id><pub-id pub-id-type="pmid">25523015</pub-id></element-citation></ref><ref id="B105-vaccines-12-00950"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alameh</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Tomb&#225;cz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bettini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lederer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sittplangkoon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wilmore</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Gaudette</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>O.Y.</given-names></name><name name-style="western"><surname>Pine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses</article-title><source>Immunity</source><year>2021</year><volume>54</volume><fpage>2877</fpage><lpage>2892.e2877</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.11.001</pub-id><pub-id pub-id-type="pmid">34852217</pub-id><pub-id pub-id-type="pmcid">PMC8566475</pub-id></element-citation></ref><ref id="B106-vaccines-12-00950"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machiels</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>van Baren</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marchand</surname><given-names>M.</given-names></name></person-group><article-title>Peptide-based cancer vaccines</article-title><source>Semin. Oncol.</source><year>2002</year><volume>29</volume><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1053/sonc.2002.35244</pub-id><pub-id pub-id-type="pmid">12407514</pub-id></element-citation></ref><ref id="B107-vaccines-12-00950"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannopoulos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dmoszynska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kowal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rolinski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gostick</surname><given-names>E.</given-names></name><name name-style="western"><surname>Price</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Greiner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rojewski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stilgenbauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>D&#246;hner</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia</article-title><source>Leukemia</source><year>2010</year><volume>24</volume><fpage>798</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1038/leu.2010.29</pub-id><pub-id pub-id-type="pmid">20220777</pub-id></element-citation></ref><ref id="B108-vaccines-12-00950"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harabuchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Celis</surname><given-names>E.</given-names></name></person-group><article-title>Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses</article-title><source>Cancer Immunol. Res.</source><year>2017</year><volume>5</volume><fpage>72</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0194</pub-id><pub-id pub-id-type="pmid">27941004</pub-id><pub-id pub-id-type="pmcid">PMC5221568</pub-id></element-citation></ref><ref id="B109-vaccines-12-00950"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Engleman</surname><given-names>E.G.</given-names></name></person-group><article-title>Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance</article-title><source>Annu. Rev. Pathol.</source><year>2021</year><volume>16</volume><fpage>223</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-042020-042741</pub-id><pub-id pub-id-type="pmid">33197221</pub-id></element-citation></ref><ref id="B110-vaccines-12-00950"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartoglu</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ames</surname><given-names>H.</given-names></name></person-group><article-title>Ensuring quality and integrity of vaccines throughout the cold chain: The role of temperature monitoring</article-title><source>Expert. Rev. Vaccines</source><year>2022</year><volume>21</volume><fpage>799</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1080/14760584.2022.2061462</pub-id><pub-id pub-id-type="pmid">35373686</pub-id></element-citation></ref><ref id="B111-vaccines-12-00950"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kristensen</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Lorenson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bartholomew</surname><given-names>K.</given-names></name><name name-style="western"><surname>Villadiego</surname><given-names>S.</given-names></name></person-group><article-title>Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>899</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.01.001</pub-id><pub-id pub-id-type="pmid">26778422</pub-id><pub-id pub-id-type="pmcid">PMC4744085</pub-id></element-citation></ref><ref id="B112-vaccines-12-00950"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartoglu</surname><given-names>U.</given-names></name><name name-style="western"><surname>Milstien</surname><given-names>J.</given-names></name></person-group><article-title>Tools and approaches to ensure quality of vaccines throughout the cold chain</article-title><source>Expert Rev. Vaccines</source><year>2014</year><volume>13</volume><fpage>843</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.923761</pub-id><pub-id pub-id-type="pmid">24865112</pub-id><pub-id pub-id-type="pmcid">PMC4743593</pub-id></element-citation></ref><ref id="B113-vaccines-12-00950"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lloyd</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lydon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ouhichi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zaffran</surname><given-names>M.</given-names></name></person-group><article-title>Reducing the loss of vaccines from accidental freezing in the cold chain: The experience of continuous temperature monitoring in Tunisia</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>902</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.10.080</pub-id><pub-id pub-id-type="pmid">25444810</pub-id><pub-id pub-id-type="pmcid">PMC4319682</pub-id></element-citation></ref><ref id="B114-vaccines-12-00950"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthias</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garrison</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Newland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C.</given-names></name></person-group><article-title>Freezing temperatures in the vaccine cold chain: A systematic literature review</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>3980</fpage><lpage>3986</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.02.052</pub-id><pub-id pub-id-type="pmid">17382434</pub-id></element-citation></ref><ref id="B115-vaccines-12-00950"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunsvig</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Aamdal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gjertsen</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Kvalheim</surname><given-names>G.</given-names></name><name name-style="western"><surname>Markowski-Grimsrud</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Sve</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dyrhaug</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trachsel</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eriksen</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Telomerase peptide vaccination: A phase I/II study in patients with non-small cell lung cancer</article-title><source>Cancer Immunol. Immunother.</source><year>2006</year><volume>55</volume><fpage>1553</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1007/s00262-006-0145-7</pub-id><pub-id pub-id-type="pmid">16491401</pub-id><pub-id pub-id-type="pmcid">PMC11030882</pub-id></element-citation></ref><ref id="B116-vaccines-12-00950"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weinschenk</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stenzl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zdrojowy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pluzanska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szczylik</surname><given-names>C.</given-names></name><name name-style="western"><surname>Staehler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brugger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Mendrzyk</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival</article-title><source>Nat. Med.</source><year>2012</year><volume>18</volume><fpage>1254</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1038/nm.2883</pub-id><pub-id pub-id-type="pmid">22842478</pub-id></element-citation></ref><ref id="B117-vaccines-12-00950"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rini</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Stenzl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zdrojowy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kogan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shkolnik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oudard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weikert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bracarda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crabb</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bedke</surname><given-names>J.</given-names></name><etal/></person-group><article-title>IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): A multicentre, open-label, randomised, controlled, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2016</year><volume>17</volume><fpage>1599</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)30408-9</pub-id><pub-id pub-id-type="pmid">27720136</pub-id></element-citation></ref><ref id="B118-vaccines-12-00950"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Clive</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benavides</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Gates</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Sears</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Stojadinovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ponniah</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02</article-title><source>Cancer</source><year>2012</year><volume>118</volume><fpage>2594</fpage><lpage>2602</lpage><pub-id pub-id-type="doi">10.1002/cncr.26574</pub-id><pub-id pub-id-type="pmid">21989902</pub-id><pub-id pub-id-type="pmcid">PMC3428069</pub-id></element-citation></ref><ref id="B119-vaccines-12-00950"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Schneble</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Echo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ponniah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peoples</surname><given-names>G.E.</given-names></name></person-group><article-title>Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients</article-title><source>Ann. Oncol.</source><year>2014</year><volume>25</volume><fpage>1735</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu211</pub-id><pub-id pub-id-type="pmid">24907636</pub-id><pub-id pub-id-type="pmcid">PMC4143091</pub-id></element-citation></ref><ref id="B120-vaccines-12-00950"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#228;ger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Drijfhout</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Karbach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ringhoffer</surname><given-names>M.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Stockert</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes</article-title><source>J. Exp. Med.</source><year>1998</year><volume>187</volume><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1084/jem.187.2.265</pub-id><pub-id pub-id-type="pmid">9432985</pub-id><pub-id pub-id-type="pmcid">PMC2212106</pub-id></element-citation></ref><ref id="B121-vaccines-12-00950"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odunsi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsuzaki</surname><given-names>J.</given-names></name><name name-style="western"><surname>James</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Mhawech-Fauceglia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Akers</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Miliotto</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer</article-title><source>Cancer Immunol. Res.</source><year>2014</year><volume>2</volume><fpage>37</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0126</pub-id><pub-id pub-id-type="pmid">24535937</pub-id><pub-id pub-id-type="pmcid">PMC3925074</pub-id></element-citation></ref><ref id="B122-vaccines-12-00950"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vansteenkiste</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zielinski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Linder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dahabreh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Malinowski</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lopez-Brea</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vanakesa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jassem</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kalofonos</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>2396</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.43.7103</pub-id><pub-id pub-id-type="pmid">23715567</pub-id></element-citation></ref><ref id="B123-vaccines-12-00950"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tsuboi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Osaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kyo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Elisseeva</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Oji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ikegame</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Induction of WT1 (Wilms&#8217; tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>13885</fpage><lpage>13890</lpage><pub-id pub-id-type="doi">10.1073/pnas.0405884101</pub-id><pub-id pub-id-type="pmid">15365188</pub-id><pub-id pub-id-type="pmcid">PMC518848</pub-id></element-citation></ref><ref id="B124-vaccines-12-00950"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Farazuddin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Janczak</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J.R.</given-names><suffix>Jr.</suffix></name></person-group><article-title>A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation</article-title><source>Cancer Gene Ther.</source><year>2024</year><volume>31</volume><fpage>464</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1038/s41417-023-00717-9</pub-id><pub-id pub-id-type="pmid">38177307</pub-id></element-citation></ref><ref id="B125-vaccines-12-00950"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Che</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name></person-group><article-title>Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>1384</elocation-id><pub-id pub-id-type="doi">10.3390/ph16101384</pub-id><pub-id pub-id-type="pmid">37895855</pub-id><pub-id pub-id-type="pmcid">PMC10610367</pub-id></element-citation></ref><ref id="B126-vaccines-12-00950"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Sousa</surname><given-names>V.M.L.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>L.</given-names></name></person-group><article-title>Heterogeneity in Lung Cancer</article-title><source>Pathobiology</source><year>2018</year><volume>85</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1159/000487440</pub-id><pub-id pub-id-type="pmid">29635240</pub-id></element-citation></ref><ref id="B127-vaccines-12-00950"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1255799</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1255799</pub-id><pub-id pub-id-type="pmid">37731507</pub-id><pub-id pub-id-type="pmcid">PMC10508181</pub-id></element-citation></ref><ref id="B128-vaccines-12-00950"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasyam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sharples</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Barrow</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mester</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Authier-Hall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dzhelali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ostapowicz</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma</article-title><source>Cancer Immunol. Immunother.</source><year>2023</year><volume>72</volume><fpage>2267</fpage><lpage>2282</lpage><pub-id pub-id-type="doi">10.1007/s00262-023-03400-y</pub-id><pub-id pub-id-type="pmid">36881133</pub-id><pub-id pub-id-type="pmcid">PMC10264280</pub-id></element-citation></ref><ref id="B129-vaccines-12-00950"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karanikas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>P.X.</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pietersz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tait</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein</article-title><source>J. Clin. Investig.</source><year>1997</year><volume>100</volume><fpage>2783</fpage><lpage>2792</lpage><pub-id pub-id-type="doi">10.1172/JCI119825</pub-id><pub-id pub-id-type="pmid">9389743</pub-id><pub-id pub-id-type="pmcid">PMC508483</pub-id></element-citation></ref><ref id="B130-vaccines-12-00950"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musselli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ragupathi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gilewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Panageas</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Spinat</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>P.O.</given-names></name></person-group><article-title>Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1</article-title><source>Int. J. Cancer</source><year>2002</year><volume>97</volume><fpage>660</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1002/ijc.10081</pub-id><pub-id pub-id-type="pmid">11807794</pub-id></element-citation></ref><ref id="B131-vaccines-12-00950"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramanathan</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>McKolanis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hitbold</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schraut</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Warnick</surname><given-names>E.</given-names></name><name name-style="western"><surname>Whiteside</surname><given-names>T.</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer</article-title><source>Cancer Immunol. Immunother.</source><year>2005</year><volume>54</volume><fpage>254</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1007/s00262-004-0581-1</pub-id><pub-id pub-id-type="pmid">15372205</pub-id><pub-id pub-id-type="pmcid">PMC11034344</pub-id></element-citation></ref><ref id="B132-vaccines-12-00950"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brayer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lancet</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>J.</given-names></name><name name-style="western"><surname>List</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balducci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Komrokji</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pinilla-Ibarz</surname><given-names>J.</given-names></name></person-group><article-title>WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides</article-title><source>Am. J. Hematol.</source><year>2015</year><volume>90</volume><fpage>602</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1002/ajh.24014</pub-id><pub-id pub-id-type="pmid">25802083</pub-id><pub-id pub-id-type="pmcid">PMC4617516</pub-id></element-citation></ref><ref id="B133-vaccines-12-00950"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zauderer</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Panageas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>W.V.</given-names></name><name name-style="western"><surname>Rimner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rusch</surname><given-names>V.W.</given-names></name><name name-style="western"><surname>Adusumilli</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma</article-title><source>Clin. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>7483</fpage><lpage>7489</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-2169</pub-id><pub-id pub-id-type="pmid">28972039</pub-id><pub-id pub-id-type="pmcid">PMC5732877</pub-id></element-citation></ref><ref id="B134-vaccines-12-00950"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Shea</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heckman-Stoddard</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Wojtowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dimond</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bedrosian</surname><given-names>I.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garber</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Husband</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ</article-title><source>Cancer Prev. Res.</source><year>2023</year><volume>16</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-22-0388</pub-id><pub-id pub-id-type="pmid">37259799</pub-id><pub-id pub-id-type="pmcid">PMC10903526</pub-id></element-citation></ref><ref id="B135-vaccines-12-00950"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Disis</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Gooley</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Rinn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Piepkorn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheever</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Knutson</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Schiffman</surname><given-names>K.</given-names></name></person-group><article-title>Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines</article-title><source>J. Clin. Oncol.</source><year>2002</year><volume>20</volume><fpage>2624</fpage><lpage>2632</lpage><pub-id pub-id-type="doi">10.1200/JCO.2002.06.171</pub-id><pub-id pub-id-type="pmid">12039923</pub-id></element-citation></ref><ref id="B136-vaccines-12-00950"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmichael</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Benavides</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gates</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ponniah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peoples</surname><given-names>G.E.</given-names></name></person-group><article-title>Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04</article-title><source>Cancer</source><year>2010</year><volume>116</volume><fpage>292</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1002/cncr.24756</pub-id><pub-id pub-id-type="pmid">19924797</pub-id></element-citation></ref><ref id="B137-vaccines-12-00950"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fran&#231;ois</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ottaviani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Renkvist</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stockis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thielemans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Colau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marchand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The CD4<sup>+</sup> T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells</article-title><source>Cancer Res.</source><year>2009</year><volume>69</volume><fpage>4335</fpage><lpage>4345</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3726</pub-id><pub-id pub-id-type="pmid">19435913</pub-id></element-citation></ref><ref id="B138-vaccines-12-00950"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshita</surname><given-names>C.</given-names></name><name name-style="western"><surname>Takikawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kume</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ashizawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iizuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kiyohara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanosaki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial</article-title><source>Oncol. Rep.</source><year>2012</year><volume>28</volume><fpage>1131</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.3892/or.2012.1956</pub-id><pub-id pub-id-type="pmid">22895835</pub-id><pub-id pub-id-type="pmcid">PMC3583475</pub-id></element-citation></ref><ref id="B139-vaccines-12-00950"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sampson</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Heimberger</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Aldape</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Herndon</surname><given-names>J.E.</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>McLendon</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>4722</fpage><lpage>4729</lpage><pub-id pub-id-type="doi">10.1200/jco.2010.28.6963</pub-id><pub-id pub-id-type="pmid">20921459</pub-id><pub-id pub-id-type="pmcid">PMC3020702</pub-id></element-citation></ref><ref id="B140-vaccines-12-00950"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Butowski</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Recht</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirte</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ashby</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mechtler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Goldlust</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial</article-title><source>Lancet Oncol.</source><year>2017</year><volume>18</volume><fpage>1373</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30517-X</pub-id><pub-id pub-id-type="pmid">28844499</pub-id></element-citation></ref><ref id="B141-vaccines-12-00950"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middleton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Silcocks</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>T.</given-names></name><name name-style="western"><surname>Valle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wadsley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Propper</surname><given-names>D.</given-names></name><name name-style="western"><surname>Coxon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>P.</given-names></name><name name-style="western"><surname>Madhusudan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roques</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2014</year><volume>15</volume><fpage>829</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70236-0</pub-id><pub-id pub-id-type="pmid">24954781</pub-id></element-citation></ref><ref id="B142-vaccines-12-00950"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schumacher</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bunse</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pusch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sahm</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wiestler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Quandt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Menn</surname><given-names>O.</given-names></name><name name-style="western"><surname>Osswald</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oezen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A vaccine targeting mutant IDH1 induces antitumour immunity</article-title><source>Nature</source><year>2014</year><volume>512</volume><fpage>324</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/nature13387</pub-id><pub-id pub-id-type="pmid">25043048</pub-id></element-citation></ref><ref id="B143-vaccines-12-00950"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenstermaker</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Ciesielski</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Mechtler</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Belal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahluwalia</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hutson</surname><given-names>A.D.</given-names></name></person-group><article-title>Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma</article-title><source>Cancer Immunol. Immunother.</source><year>2016</year><volume>65</volume><fpage>1339</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1007/s00262-016-1890-x</pub-id><pub-id pub-id-type="pmid">27576783</pub-id><pub-id pub-id-type="pmcid">PMC5069322</pub-id></element-citation></ref><ref id="B144-vaccines-12-00950"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahluwalia</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Reardon</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Abad</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Curry</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Figel</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Mechtler</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Peereboom</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Hutson</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Withers</surname><given-names>H.G.</given-names></name><etal/></person-group><article-title>Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>1453</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.00996</pub-id><pub-id pub-id-type="pmid">36521103</pub-id><pub-id pub-id-type="pmcid">PMC9995096</pub-id></element-citation></ref><ref id="B145-vaccines-12-00950"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.H.</given-names></name></person-group><article-title>Cancer vaccines: Targeting KRAS-driven cancers</article-title><source>Expert Rev. Vaccines</source><year>2020</year><volume>19</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1080/14760584.2020.1733420</pub-id><pub-id pub-id-type="pmid">32174221</pub-id></element-citation></ref><ref id="B146-vaccines-12-00950"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Correale</surname><given-names>P.</given-names></name><name name-style="western"><surname>Botta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Staropoli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nardone</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pastina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ulivieri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gandolfo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baldari</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Lazzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ciliberto</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>20539</fpage><lpage>20554</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24993</pub-id><pub-id pub-id-type="pmid">29755670</pub-id><pub-id pub-id-type="pmcid">PMC5945541</pub-id></element-citation></ref><ref id="B147-vaccines-12-00950"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gjertsen</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Buanes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rosseland</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Bakka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gladhaug</surname><given-names>I.</given-names></name><name name-style="western"><surname>S&#248;reide</surname><given-names>O.</given-names></name><name name-style="western"><surname>Eriksen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baksaas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lothe</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma</article-title><source>Int. J. Cancer</source><year>2001</year><volume>92</volume><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1002/ijc.1205</pub-id><pub-id pub-id-type="pmid">11291084</pub-id></element-citation></ref><ref id="B148-vaccines-12-00950"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Postow</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>J.D.</given-names></name></person-group><article-title>Immune Checkpoint Blockade in Cancer Therapy</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>1974</fpage><lpage>1982</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.4358</pub-id><pub-id pub-id-type="pmid">25605845</pub-id><pub-id pub-id-type="pmcid">PMC4980573</pub-id></element-citation></ref><ref id="B149-vaccines-12-00950"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Disis</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Grabstein</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Sleath</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Cheever</surname><given-names>M.A.</given-names></name></person-group><article-title>Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine</article-title><source>Clin. Cancer Res.</source><year>1999</year><volume>5</volume><fpage>1289</fpage><lpage>1297</lpage><pub-id pub-id-type="pmid">10389911</pub-id></element-citation></ref><ref id="B150-vaccines-12-00950"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>O&#8217;Day</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hassel</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1003466</pub-id><pub-id pub-id-type="pmid">20525992</pub-id><pub-id pub-id-type="pmcid">PMC3549297</pub-id></element-citation></ref><ref id="B151-vaccines-12-00950"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motz</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Coukos</surname><given-names>G.</given-names></name></person-group><article-title>Deciphering and reversing tumor immune suppression</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>61</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.005</pub-id><pub-id pub-id-type="pmid">23890064</pub-id><pub-id pub-id-type="pmcid">PMC3782392</pub-id></element-citation></ref><ref id="B152-vaccines-12-00950"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baxevanis</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Papamichail</surname><given-names>M.</given-names></name></person-group><article-title>Cancer immunotherapy</article-title><source>Crit. Rev. Clin. Lab. Sci.</source><year>2009</year><volume>46</volume><fpage>167</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1080/10408360902937809</pub-id><pub-id pub-id-type="pmid">19650714</pub-id></element-citation></ref><ref id="B153-vaccines-12-00950"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demaria</surname><given-names>S.</given-names></name><name name-style="western"><surname>Formenti</surname><given-names>S.C.</given-names></name></person-group><article-title>Role of T lymphocytes in tumor response to radiotherapy</article-title><source>Front. Oncol.</source><year>2012</year><volume>2</volume><elocation-id>95</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2012.00095</pub-id><pub-id pub-id-type="pmid">22937524</pub-id><pub-id pub-id-type="pmcid">PMC3426850</pub-id></element-citation></ref><ref id="B154-vaccines-12-00950"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schlemmer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Adjemian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Michaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sukkurwala</surname><given-names>A.Q.</given-names></name><name name-style="western"><surname>Menger</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy</article-title><source>Cancer Metastasis Rev.</source><year>2011</year><volume>30</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s10555-011-9273-4</pub-id><pub-id pub-id-type="pmid">21249425</pub-id></element-citation></ref><ref id="B155-vaccines-12-00950"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slingluff</surname><given-names>C.L.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Petroni</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Chianese-Bullock</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Smolkin</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>von Mehren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grosh</surname><given-names>W.W.</given-names></name></person-group><article-title>Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine</article-title><source>J. Clin. Oncol.</source><year>2011</year><volume>29</volume><fpage>2924</fpage><lpage>2932</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.33.8053</pub-id><pub-id pub-id-type="pmid">21690475</pub-id><pub-id pub-id-type="pmcid">PMC3138719</pub-id></element-citation></ref><ref id="B156-vaccines-12-00950"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iinuma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fukushima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Inaba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>J.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Horikawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsutani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients</article-title><source>J. Transl. Med.</source><year>2014</year><volume>12</volume><fpage>84</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-12-84</pub-id><pub-id pub-id-type="pmid">24708624</pub-id><pub-id pub-id-type="pmcid">PMC4234129</pub-id></element-citation></ref><ref id="B157-vaccines-12-00950"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seidel</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kabashima</surname><given-names>K.</given-names></name></person-group><article-title>Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations</article-title><source>Front. Oncol.</source><year>2018</year><volume>8</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2018.00086</pub-id><pub-id pub-id-type="pmid">29644214</pub-id><pub-id pub-id-type="pmcid">PMC5883082</pub-id></element-citation></ref><ref id="B158-vaccines-12-00950"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igarashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sasada</surname><given-names>T.</given-names></name></person-group><article-title>Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy</article-title><source>J. Immunol. Res.</source><year>2020</year><volume>2020</volume><fpage>5825401</fpage><pub-id pub-id-type="doi">10.1155/2020/5825401</pub-id><pub-id pub-id-type="pmid">33282961</pub-id><pub-id pub-id-type="pmcid">PMC7685825</pub-id></element-citation></ref><ref id="B159-vaccines-12-00950"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trac</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E.J.</given-names></name></person-group><article-title>Peptide-based targeting of immunosuppressive cells in cancer</article-title><source>Bioact. Mater.</source><year>2020</year><volume>5</volume><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2020.01.006</pub-id><pub-id pub-id-type="pmid">31956738</pub-id><pub-id pub-id-type="pmcid">PMC6962647</pub-id></element-citation></ref><ref id="B160-vaccines-12-00950"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huff</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Longway</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Andaloori</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davis-Marcisak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lyman</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>B.</given-names></name><etal/></person-group><article-title>CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy</article-title><source>JCI Insight</source><year>2023</year><volume>8</volume><fpage>e174027</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.174027</pub-id><pub-id pub-id-type="pmid">38063199</pub-id><pub-id pub-id-type="pmcid">PMC10795827</pub-id></element-citation></ref><ref id="B161-vaccines-12-00950"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Massarelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>William</surname><given-names>W.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kies</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferrarotto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.U.</given-names></name><etal/></person-group><article-title>Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial</article-title><source>JAMA Oncol.</source><year>2019</year><volume>5</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2018.4051</pub-id><pub-id pub-id-type="pmid">30267032</pub-id><pub-id pub-id-type="pmcid">PMC6439768</pub-id></element-citation></ref><ref id="B162-vaccines-12-00950"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hijikata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okazaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Murahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0187878</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0187878</pub-id><pub-id pub-id-type="pmid">29293510</pub-id><pub-id pub-id-type="pmcid">PMC5749706</pub-id></element-citation></ref><ref id="B163-vaccines-12-00950"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirahama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Muroya</surname><given-names>D.</given-names></name><name name-style="western"><surname>Matsueda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shichijo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Naito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer</article-title><source>Cancer Sci.</source><year>2017</year><volume>108</volume><fpage>838</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1111/cas.13193</pub-id><pub-id pub-id-type="pmid">28188670</pub-id><pub-id pub-id-type="pmcid">PMC5448649</pub-id></element-citation></ref><ref id="B164-vaccines-12-00950"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.P.</given-names></name><etal/></person-group><article-title>Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma</article-title><source>World J. Gastroenterol.</source><year>2017</year><volume>23</volume><fpage>5395</fpage><lpage>5404</lpage><pub-id pub-id-type="doi">10.3748/wjg.v23.i29.5395</pub-id><pub-id pub-id-type="pmid">28839440</pub-id><pub-id pub-id-type="pmcid">PMC5550789</pub-id></element-citation></ref><ref id="B165-vaccines-12-00950"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name></person-group><article-title>Immunogenic cell death in cancer therapy</article-title><source>Annu. Rev. Immunol.</source><year>2013</year><volume>31</volume><fpage>51</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-100008</pub-id><pub-id pub-id-type="pmid">23157435</pub-id></element-citation></ref><ref id="B166-vaccines-12-00950"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Aznar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Korman</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>P&#233;rez Gracia</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>J.</given-names></name></person-group><article-title>Evolving synergistic combinations of targeted immunotherapies to combat cancer</article-title><source>Nat. Rev. Cancer</source><year>2015</year><volume>15</volume><fpage>457</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1038/nrc3973</pub-id><pub-id pub-id-type="pmid">26205340</pub-id></element-citation></ref><ref id="B167-vaccines-12-00950"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Apetoh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ghiringhelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tesniere</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>The anticancer immune response: Indispensable for therapeutic success?</article-title><source>J. Clin. Investig.</source><year>2008</year><volume>118</volume><fpage>1991</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1172/JCI35180</pub-id><pub-id pub-id-type="pmid">18523649</pub-id><pub-id pub-id-type="pmcid">PMC2396905</pub-id></element-citation></ref><ref id="B168-vaccines-12-00950"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>74</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.06.014</pub-id><pub-id pub-id-type="pmid">23890065</pub-id></element-citation></ref><ref id="B169-vaccines-12-00950"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Preet Kaur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alice</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crittenden</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Gough</surname><given-names>M.J.</given-names></name></person-group><article-title>The role of dendritic cells in radiation-induced immune responses</article-title><source>Int. Rev. Cell Mol. Biol.</source><year>2023</year><volume>378</volume><fpage>61</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/bs.ircmb.2023.02.002</pub-id><pub-id pub-id-type="pmid">37438021</pub-id></element-citation></ref><ref id="B170-vaccines-12-00950"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>N.</given-names></name><name name-style="western"><surname>Braunstein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Badura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Babb</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Formenti</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Dustin</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>3099</fpage><lpage>3107</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.5.3099</pub-id><pub-id pub-id-type="pmid">18713980</pub-id><pub-id pub-id-type="pmcid">PMC2587101</pub-id></element-citation></ref><ref id="B171-vaccines-12-00950"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaue</surname><given-names>D.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>W.H.</given-names></name></person-group><article-title>T lymphocytes and normal tissue responses to radiation</article-title><source>Front. Oncol.</source><year>2012</year><volume>2</volume><elocation-id>119</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2012.00119</pub-id><pub-id pub-id-type="pmid">23050243</pub-id><pub-id pub-id-type="pmcid">PMC3445965</pub-id></element-citation></ref><ref id="B172-vaccines-12-00950"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garnett</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Palena</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Schlom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hodge</surname><given-names>J.W.</given-names></name></person-group><article-title>Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>7985</fpage><lpage>7994</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1525</pub-id><pub-id pub-id-type="pmid">15520206</pub-id></element-citation></ref><ref id="B173-vaccines-12-00950"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sallusto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Araki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>From vaccines to memory and back</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>451</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.008</pub-id><pub-id pub-id-type="pmid">21029957</pub-id><pub-id pub-id-type="pmcid">PMC3760154</pub-id></element-citation></ref><ref id="B174-vaccines-12-00950"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulley</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Arlen</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Pazdur</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Skarupa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Poole</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Hodge</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer</article-title><source>Cancer Immunol. Immunother.</source><year>2010</year><volume>59</volume><fpage>663</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1007/s00262-009-0782-8</pub-id><pub-id pub-id-type="pmid">19890632</pub-id><pub-id pub-id-type="pmcid">PMC2832083</pub-id></element-citation></ref><ref id="B175-vaccines-12-00950"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cladel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Balogh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>N.</given-names></name></person-group><article-title>Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>3706</fpage><lpage>3713</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.03.015</pub-id><pub-id pub-id-type="pmid">20332046</pub-id><pub-id pub-id-type="pmcid">PMC2879011</pub-id></element-citation></ref><ref id="B176-vaccines-12-00950"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Mariscal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Posadas</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Uc</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Ortega-Olvera</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>S.</given-names></name></person-group><article-title>Strategies that Target Tight Junctions for Enhanced Drug Delivery</article-title><source>Curr. Pharm. Des.</source><year>2016</year><volume>22</volume><fpage>5313</fpage><lpage>5346</lpage><pub-id pub-id-type="doi">10.2174/1381612822666160720163656</pub-id><pub-id pub-id-type="pmid">27510485</pub-id></element-citation></ref><ref id="B177-vaccines-12-00950"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Delair</surname><given-names>T.</given-names></name></person-group><article-title>Chitosan-based Colloidal Polyelectrolyte Complexes for Drug Delivery: A Review</article-title><source>Carbohydr. Polym.</source><year>2020</year><volume>238</volume><fpage>116126</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2020.116126</pub-id><pub-id pub-id-type="pmid">32299572</pub-id></element-citation></ref><ref id="B178-vaccines-12-00950"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolhassani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Safaiyan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rafati</surname><given-names>S.</given-names></name></person-group><article-title>Improvement of different vaccine delivery systems for cancer therapy</article-title><source>Mol. Cancer</source><year>2011</year><volume>10</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-10-3</pub-id><pub-id pub-id-type="pmid">21211062</pub-id><pub-id pub-id-type="pmcid">PMC3024302</pub-id></element-citation></ref><ref id="B179-vaccines-12-00950"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goand</surname><given-names>U.K.</given-names></name><name name-style="western"><surname>Husain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Katekar</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gayen</surname><given-names>J.R.</given-names></name></person-group><article-title>Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability</article-title><source>Drug Dev. Res.</source><year>2021</year><volume>82</volume><fpage>927</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1002/ddr.21832</pub-id><pub-id pub-id-type="pmid">33988872</pub-id></element-citation></ref><ref id="B180-vaccines-12-00950"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Advancedoral vaccine delivery strategies for improving the immunity</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>177</volume><fpage>113928</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.113928</pub-id><pub-id pub-id-type="pmid">34411689</pub-id></element-citation></ref><ref id="B181-vaccines-12-00950"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunisawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kurashima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>H.</given-names></name></person-group><article-title>Gut-associated lymphoid tissues for the development of oral vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><year>2012</year><volume>64</volume><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2011.07.003</pub-id><pub-id pub-id-type="pmid">21827802</pub-id></element-citation></ref><ref id="B182-vaccines-12-00950"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshweiat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ambrus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Csoka</surname><given-names>I.</given-names></name></person-group><article-title>Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery</article-title><source>Curr. Med. Chem.</source><year>2019</year><volume>26</volume><fpage>6459</fpage><lpage>6492</lpage><pub-id pub-id-type="doi">10.2174/0929867326666190827151741</pub-id><pub-id pub-id-type="pmid">31453778</pub-id></element-citation></ref><ref id="B183-vaccines-12-00950"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schluns</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Sastry</surname><given-names>K.J.</given-names></name></person-group><article-title>Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e90001</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0090001</pub-id><pub-id pub-id-type="pmid">24599269</pub-id><pub-id pub-id-type="pmcid">PMC3943861</pub-id></element-citation></ref><ref id="B184-vaccines-12-00950"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Disis</surname><given-names>M.L.</given-names></name></person-group><article-title>Immune regulation of cancer</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>4531</fpage><lpage>4538</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.27.2146</pub-id><pub-id pub-id-type="pmid">20516428</pub-id><pub-id pub-id-type="pmcid">PMC3041789</pub-id></element-citation></ref><ref id="B185-vaccines-12-00950"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daiko</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marafioti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shirakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakatsura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Puccio</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hikichi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshimura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients</article-title><source>Cancer Immunol. Immunother.</source><year>2020</year><volume>69</volume><fpage>2247</fpage><lpage>2257</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02619-3</pub-id><pub-id pub-id-type="pmid">32500232</pub-id><pub-id pub-id-type="pmcid">PMC7568713</pub-id></element-citation></ref><ref id="B186-vaccines-12-00950"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slingluff</surname><given-names>C.L.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Petroni</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Yamshchikov</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Barnd</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Eastham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galavotti</surname><given-names>H.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Deacon</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Hibbitts</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teates</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells</article-title><source>J. Clin. Oncol.</source><year>2003</year><volume>21</volume><fpage>4016</fpage><lpage>4026</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.10.005</pub-id><pub-id pub-id-type="pmid">14581425</pub-id></element-citation></ref><ref id="B187-vaccines-12-00950"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Disis</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Gooley</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Slota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Coveler</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Childs</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Fintak</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer</article-title><source>J. Clin. Oncol.</source><year>2009</year><volume>27</volume><fpage>4685</fpage><lpage>4692</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.20.6789</pub-id><pub-id pub-id-type="pmid">19720923</pub-id><pub-id pub-id-type="pmcid">PMC2754913</pub-id></element-citation></ref><ref id="B188-vaccines-12-00950"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiwara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Omori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugimura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ohue</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mochizuki</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Multiple therapeutic peptide vaccines for patients with advanced gastric cancer</article-title><source>Int. J. Oncol.</source><year>2017</year><volume>50</volume><fpage>1655</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.3892/ijo.2017.3955</pub-id><pub-id pub-id-type="pmid">28393243</pub-id></element-citation></ref><ref id="B189-vaccines-12-00950"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishihara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kitano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Muraoka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Momose</surname><given-names>F.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miyahara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma</article-title><source>Int. J. Cancer</source><year>2023</year><volume>152</volume><fpage>2554</fpage><lpage>2566</lpage><pub-id pub-id-type="doi">10.1002/ijc.34453</pub-id><pub-id pub-id-type="pmid">36727538</pub-id></element-citation></ref><ref id="B190-vaccines-12-00950"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Yamada-Nakata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishihara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuwae</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ammori</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tsuboi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oji</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children</article-title><source>Pediatr. Blood Cancer</source><year>2016</year><volume>63</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1002/pbc.25792</pub-id><pub-id pub-id-type="pmid">26469989</pub-id></element-citation></ref><ref id="B191-vaccines-12-00950"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrack</surname><given-names>P.</given-names></name><name name-style="western"><surname>McKee</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Munks</surname><given-names>M.W.</given-names></name></person-group><article-title>Towards an understanding of the adjuvant action of aluminium</article-title><source>Nat. Rev. Immunol.</source><year>2009</year><volume>9</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/nri2510</pub-id><pub-id pub-id-type="pmid">19247370</pub-id><pub-id pub-id-type="pmcid">PMC3147301</pub-id></element-citation></ref><ref id="B192-vaccines-12-00950"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name></person-group><article-title>Development of TLR9 agonists for cancer therapy</article-title><source>J. Clin. Investig.</source><year>2007</year><volume>117</volume><fpage>1184</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1172/JCI31414</pub-id><pub-id pub-id-type="pmid">17476348</pub-id><pub-id pub-id-type="pmcid">PMC1857270</pub-id></element-citation></ref><ref id="B193-vaccines-12-00950"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>Key roles of adjuvants in modern vaccines</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1597</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1038/nm.3409</pub-id><pub-id pub-id-type="pmid">24309663</pub-id></element-citation></ref><ref id="B194-vaccines-12-00950"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Teymouri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nikpoor</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Navashenaq</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Gholizadeh</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Darban</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Jaafari</surname><given-names>M.R.</given-names></name></person-group><article-title>Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer</article-title><source>Eur. J. Cancer</source><year>2020</year><volume>129</volume><fpage>80</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2020.01.010</pub-id><pub-id pub-id-type="pmid">32145473</pub-id></element-citation></ref><ref id="B195-vaccines-12-00950"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atzpodien</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fluck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reitz</surname><given-names>M.</given-names></name></person-group><article-title>Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients</article-title><source>Cancer Biother. Radiopharm.</source><year>2004</year><volume>19</volume><fpage>758</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1089/cbr.2004.19.758</pub-id><pub-id pub-id-type="pmid">15665624</pub-id></element-citation></ref><ref id="B196-vaccines-12-00950"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butterfield</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tarhini</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Margolin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>White</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Whiteside</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kirkwood</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)</article-title><source>Clin. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>5034</fpage><lpage>5043</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-3016</pub-id><pub-id pub-id-type="pmid">28536308</pub-id><pub-id pub-id-type="pmcid">PMC5581724</pub-id></element-citation></ref><ref id="B197-vaccines-12-00950"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dranoff</surname><given-names>G.</given-names></name></person-group><article-title>GM-CSF-secreting melanoma vaccines</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>3188</fpage><lpage>3192</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206459</pub-id><pub-id pub-id-type="pmid">12789295</pub-id></element-citation></ref><ref id="B198-vaccines-12-00950"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B.Z.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Q.L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>D.Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>GM-CSF alters dendritic cells in autoimmune diseases</article-title><source>Autoimmunity</source><year>2013</year><volume>46</volume><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.3109/08916934.2013.803533</pub-id><pub-id pub-id-type="pmid">23786272</pub-id></element-citation></ref><ref id="B199-vaccines-12-00950"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Fritzell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Badn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Eberst&#229;l</surname><given-names>S.</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Visse</surname><given-names>E.</given-names></name><name name-style="western"><surname>Darabi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Siesj&#246;</surname><given-names>P.</given-names></name></person-group><article-title>Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells</article-title><source>Int. J. Cancer</source><year>2009</year><volume>124</volume><fpage>630</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1002/ijc.23986</pub-id><pub-id pub-id-type="pmid">18972433</pub-id></element-citation></ref><ref id="B200-vaccines-12-00950"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM-CSF and IL-12, enhance the anti-renal cortical adenocarcinoma effect</article-title><source>Oncol. Rep.</source><year>2019</year><volume>42</volume><fpage>866</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.3892/or.2019.7208</pub-id><pub-id pub-id-type="pmid">31233203</pub-id></element-citation></ref><ref id="B201-vaccines-12-00950"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanzler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barrat</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Hessel</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>R.L.</given-names></name></person-group><article-title>Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists</article-title><source>Nat. Med.</source><year>2007</year><volume>13</volume><fpage>552</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1038/nm1589</pub-id><pub-id pub-id-type="pmid">17479101</pub-id></element-citation></ref><ref id="B202-vaccines-12-00950"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name></person-group><article-title>CpG motifs in bacterial DNA and their immune effects</article-title><source>Annu. Rev. Immunol.</source><year>2002</year><volume>20</volume><fpage>709</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.20.100301.064842</pub-id><pub-id pub-id-type="pmid">11861616</pub-id></element-citation></ref><ref id="B203-vaccines-12-00950"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirota</surname><given-names>H.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><article-title>Recent progress concerning CpG DNA and its use as a vaccine adjuvant</article-title><source>Expert. Rev. Vaccines</source><year>2014</year><volume>13</volume><fpage>299</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.863715</pub-id><pub-id pub-id-type="pmid">24308579</pub-id><pub-id pub-id-type="pmcid">PMC6335645</pub-id></element-citation></ref><ref id="B204-vaccines-12-00950"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speiser</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Li&#233;nard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rufer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rubio-Godoy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rimoldi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lejeune</surname><given-names>F.</given-names></name><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Cerottini</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>P.</given-names></name></person-group><article-title>Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909</article-title><source>J. Clin. Investig.</source><year>2005</year><volume>115</volume><fpage>739</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1172/JCI23373</pub-id><pub-id pub-id-type="pmid">15696196</pub-id><pub-id pub-id-type="pmcid">PMC546459</pub-id></element-citation></ref><ref id="B205-vaccines-12-00950"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomann</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Heurtault</surname><given-names>B.</given-names></name><name name-style="western"><surname>Weidner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bray&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beyrath</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fournel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schuber</surname><given-names>F.</given-names></name><name name-style="western"><surname>Frisch</surname><given-names>B.</given-names></name></person-group><article-title>Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>4574</fpage><lpage>4583</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.03.015</pub-id><pub-id pub-id-type="pmid">21474175</pub-id></element-citation></ref><ref id="B206-vaccines-12-00950"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>HogenEsch</surname><given-names>H.</given-names></name></person-group><article-title>Mechanisms of stimulation of the immune response by aluminum adjuvants</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><issue>(Suppl. S3)</issue><fpage>S34</fpage><lpage>S39</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00169-X</pub-id><pub-id pub-id-type="pmid">12184362</pub-id></element-citation></ref><ref id="B207-vaccines-12-00950"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>A.</given-names></name></person-group><article-title>The mechanism of action of MF59&#8212;An innately attractive adjuvant formulation</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>4341</fpage><lpage>4348</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.061</pub-id><pub-id pub-id-type="pmid">22682289</pub-id></element-citation></ref><ref id="B208-vaccines-12-00950"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name></person-group><article-title>From discovery to licensure, the Adjuvant System story</article-title><source>Hum. Vaccin. Immunother.</source><year>2017</year><volume>13</volume><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1225635</pub-id><pub-id pub-id-type="pmid">27636098</pub-id><pub-id pub-id-type="pmcid">PMC5287309</pub-id></element-citation></ref><ref id="B209-vaccines-12-00950"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name></person-group><article-title>Therapeutic potential of Toll-like receptor 9 activation</article-title><source>Nat. Rev. Drug Discov.</source><year>2006</year><volume>5</volume><fpage>471</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1038/nrd2059</pub-id><pub-id pub-id-type="pmid">16763660</pub-id></element-citation></ref><ref id="B210-vaccines-12-00950"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kensil</surname><given-names>C.R.</given-names></name></person-group><article-title>Saponins as vaccine adjuvants</article-title><source>Crit. Rev. Ther. Drug Carrier Syst.</source><year>1996</year><volume>13</volume><fpage>1</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">8853958</pub-id></element-citation></ref><ref id="B211-vaccines-12-00950"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name></person-group><article-title>Toll-like receptor signalling</article-title><source>Nat. Rev. Immunol.</source><year>2004</year><volume>4</volume><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/nri1391</pub-id><pub-id pub-id-type="pmid">15229469</pub-id></element-citation></ref><ref id="B212-vaccines-12-00950"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>D.</given-names></name></person-group><article-title>Nanoparticle drug delivery systems: An excellent carrier for tumor peptide vaccines</article-title><source>Drug Deliv.</source><year>2018</year><volume>25</volume><fpage>1319</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1080/10717544.2018.1477857</pub-id><pub-id pub-id-type="pmid">29869539</pub-id><pub-id pub-id-type="pmcid">PMC6058474</pub-id></element-citation></ref><ref id="B213-vaccines-12-00950"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozako</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arima</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yoshimitsu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Soeda</surname><given-names>S.</given-names></name></person-group><article-title>Liposomes and nanotechnology in drug development: Focus on oncotargets</article-title><source>Int. J. Nanomed.</source><year>2012</year><volume>7</volume><fpage>4943</fpage><lpage>4951</lpage><pub-id pub-id-type="doi">10.2147/IJN.S30726</pub-id><pub-id pub-id-type="pmcid">PMC3446859</pub-id><pub-id pub-id-type="pmid">23028222</pub-id></element-citation></ref><ref id="B214-vaccines-12-00950"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name></person-group><article-title>Smart nanoparticles for cancer therapy</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>418</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01642-x</pub-id><pub-id pub-id-type="pmid">37919282</pub-id><pub-id pub-id-type="pmcid">PMC10622502</pub-id></element-citation></ref><ref id="B215-vaccines-12-00950"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>R.</given-names></name></person-group><article-title>Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle</article-title><source>Biomed. Pharmacother.</source><year>2017</year><volume>85</volume><fpage>160</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2016.11.132</pub-id><pub-id pub-id-type="pmid">27930982</pub-id></element-citation></ref><ref id="B216-vaccines-12-00950"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hills</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Shenton</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Carlisle</surname><given-names>R.C.</given-names></name></person-group><article-title>A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response</article-title><source>Eur. J. Pharm. Sci.</source><year>2020</year><volume>152</volume><fpage>105456</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105456</pub-id><pub-id pub-id-type="pmid">32653563</pub-id></element-citation></ref><ref id="B217-vaccines-12-00950"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mallapragada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name></person-group><article-title>Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents</article-title><source>J. Control Release</source><year>2013</year><volume>172</volume><fpage>1020</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.10.012</pub-id><pub-id pub-id-type="pmid">24140748</pub-id></element-citation></ref><ref id="B218-vaccines-12-00950"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fr&#233;zard</surname><given-names>F.</given-names></name></person-group><article-title>Liposomes: From biophysics to the design of peptide vaccines</article-title><source>Braz. J. Med. Biol. Res.</source><year>1999</year><volume>32</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1590/S0100-879X1999000200006</pub-id><pub-id pub-id-type="pmid">10347753</pub-id></element-citation></ref><ref id="B219-vaccines-12-00950"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boks</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bruijns</surname><given-names>S.C.M.</given-names></name><name name-style="western"><surname>Ambrosini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kalay</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Bloois</surname><given-names>L.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gruijl</surname><given-names>T.</given-names></name><name name-style="western"><surname>van Kooyk</surname><given-names>Y.</given-names></name></person-group><article-title>In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells</article-title><source>J. Investig. Dermatol.</source><year>2015</year><volume>135</volume><fpage>2697</fpage><lpage>2704</lpage><pub-id pub-id-type="doi">10.1038/jid.2015.226</pub-id><pub-id pub-id-type="pmid">26083554</pub-id></element-citation></ref><ref id="B220-vaccines-12-00950"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kirberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name></person-group><article-title>Design of nanomaterial based systems for novel vaccine development</article-title><source>Biomater. Sci.</source><year>2016</year><volume>4</volume><fpage>785</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1039/C5BM00507H</pub-id><pub-id pub-id-type="pmid">26891972</pub-id></element-citation></ref><ref id="B221-vaccines-12-00950"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wanjale</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>G.S.V.</given-names></name></person-group><article-title>Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma</article-title><source>Expert. Opin. Drug Deliv.</source><year>2017</year><volume>14</volume><fpage>811</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1080/17425247.2017.1242574</pub-id><pub-id pub-id-type="pmid">27690671</pub-id></element-citation></ref><ref id="B222-vaccines-12-00950"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peeler</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Olshefsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sylvestre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stayton</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Pun</surname><given-names>S.H.</given-names></name></person-group><article-title>Well-Defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity</article-title><source>Adv. Healthc. Mater.</source><year>2022</year><volume>11</volume><fpage>e2101651</fpage><pub-id pub-id-type="doi">10.1002/adhm.202101651</pub-id><pub-id pub-id-type="pmid">34706166</pub-id><pub-id pub-id-type="pmcid">PMC9043035</pub-id></element-citation></ref><ref id="B223-vaccines-12-00950"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Luu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yazdani</surname><given-names>O.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stayton</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Pun</surname><given-names>S.H.</given-names></name></person-group><article-title>A mannosylated polymer with endosomal release properties for peptide antigen delivery</article-title><source>J. Control Release</source><year>2023</year><volume>356</volume><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.03.004</pub-id><pub-id pub-id-type="pmid">36878319</pub-id><pub-id pub-id-type="pmcid">PMC10693254</pub-id></element-citation></ref><ref id="B224-vaccines-12-00950"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Gold Nanoparticles: Recent Advances in the Biomedical Applications</article-title><source>Cell Biochem. Biophys.</source><year>2015</year><volume>72</volume><fpage>771</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1007/s12013-015-0529-4</pub-id><pub-id pub-id-type="pmid">25663504</pub-id></element-citation></ref><ref id="B225-vaccines-12-00950"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Gonon</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#233;cheur</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Pezet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villiers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marche</surname><given-names>P.N.</given-names></name></person-group><article-title>Impact of Gold Nanoparticles on the Functions of Macrophages and Dendritic Cells</article-title><source>Cells</source><year>2021</year><volume>10</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.3390/cells10010096</pub-id><pub-id pub-id-type="pmid">33430453</pub-id><pub-id pub-id-type="pmcid">PMC7826823</pub-id></element-citation></ref><ref id="B226-vaccines-12-00950"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name></person-group><article-title>The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment</article-title><source>Bioact. Mater.</source><year>2021</year><volume>6</volume><fpage>1973</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2020.12.010</pub-id><pub-id pub-id-type="pmid">33426371</pub-id><pub-id pub-id-type="pmcid">PMC7773537</pub-id></element-citation></ref><ref id="B227-vaccines-12-00950"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>J.P.M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Figueroa</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Drezek</surname><given-names>R.A.</given-names></name></person-group><article-title>In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models</article-title><source>Small</source><year>2015</year><volume>11</volume><fpage>1453</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1002/smll.201402179</pub-id><pub-id pub-id-type="pmid">25354691</pub-id><pub-id pub-id-type="pmcid">PMC4373976</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-00950-f001" orientation="portrait"><label>Figure 1</label><caption><p>Preparation and mechanism of peptide cancer vaccine. Peptide-based cancer vaccines stimulate the immune system to target and destroy cancer cells by using synthesized peptides that represent specific antigens overexpressed or unique to cancer cells, which are formulated with adjuvants and presented by APCs to T cells, thereby activating them to attack cancer cells and potentially forming memory T cells to prevent recurrence. APCs: antigen-presenting cells; TCR: T-cell receptors; MHC: major histocompatibility complex; CTLs: cytotoxic T lymphocytes. Created with <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biorender.com">https://www.biorender.com</uri>, accessed on 1 June 2024.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-12-00950-g001.jpg"/></fig><fig position="float" id="vaccines-12-00950-f002" orientation="portrait"><label>Figure 2</label><caption><p>Peptide-based cancer vaccines combined with immunotherapy, radiotherapy, and chemotherapy. Combining peptide-based cancer vaccines with immunotherapy drugs enhances the priming and expansion of T cells while reducing immunosuppressive cells such as Tregs and MDSCs, leading to improved tumoricidal efficacy and survival outcomes in clinical trials. Additionally, combining these vaccines with chemotherapy has shown to strengthen anti-tumor immune responses, boost T cell activation, and improve OS in patients, while their combination with radiation therapy induces immunogenic cell death, promotes the release and uptake of TAAs by APCs, enhances T cell activation, and stabilizes disease progression in clinical trials. APCs: antigen-presenting cells; Tregs: regulatory T cells; MDSCs: myeloid-derived suppressor cells; OS: overall survival. Created with <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biorender.com">https://www.biorender.com</uri>, accessed on 1 June 2024.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-12-00950-g002.jpg"/></fig><table-wrap position="float" id="vaccines-12-00950-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-00950-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of characteristics of different types of tumor antigens.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Antigens</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Class of Tumor Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tumor Specificity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Example of Tumor Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunogenicity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunotherapy Strategy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">TAAs</td><td align="center" valign="middle" rowspan="1" colspan="1">Overexpressed antigens</td><td align="center" valign="middle" rowspan="1" colspan="1">Normal proteins overexpressed in tumor cells.</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" rowspan="1" colspan="1">HER2 in breast cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">Moderate</td><td align="center" valign="middle" rowspan="1" colspan="1">Targeted antibody therapies</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B70-vaccines-12-00950" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-12-00950" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Differentiation antigens</td><td align="center" valign="middle" rowspan="1" colspan="1">Proteins associated with the differentiated state, present in both tumor and tissue of origin.</td><td align="center" valign="middle" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" rowspan="1" colspan="1">MART-1 in melanoma</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td><td align="center" valign="middle" rowspan="1" colspan="1">Peptide vaccines, T-cell therapies</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B72-vaccines-12-00950" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-12-00950" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer-testis antigens</td><td align="center" valign="middle" rowspan="1" colspan="1">Normally expressed only in the testis but found in various tumors.</td><td align="center" valign="middle" rowspan="1" colspan="1">Moderate</td><td align="center" valign="middle" rowspan="1" colspan="1">NY-ESO-1 in melanoma</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td><td align="center" valign="middle" rowspan="1" colspan="1">Cancer vaccines, adoptive T-cell transfer</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B74-vaccines-12-00950" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-12-00950" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-12-00950" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncofetal antigens</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Expressed during fetal development and re-expressed in tumors.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CEA in colorectal cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibody&#8211;drug conjugates, vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-vaccines-12-00950" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-12-00950" ref-type="bibr">78</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">TSAs</td><td align="center" valign="middle" rowspan="1" colspan="1">Viral antigens</td><td align="center" valign="middle" rowspan="1" colspan="1">From oncogenic viruses, absent in normal cells.</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td><td align="center" valign="middle" rowspan="1" colspan="1">HPV E6 and E7 in cervical cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td><td align="center" valign="middle" rowspan="1" colspan="1">Preventive vaccines, therapeutic vaccines</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B79-vaccines-12-00950" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-12-00950" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-12-00950" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neoantigens</td><td align="center" valign="middle" rowspan="1" colspan="1">Unique antigens from tumor-specific alterations.</td><td align="center" valign="middle" rowspan="1" colspan="1">High</td><td align="center" valign="middle" rowspan="1" colspan="1">KRAS G12D in various cancers</td><td align="center" valign="middle" rowspan="1" colspan="1">Very High</td><td align="center" valign="middle" rowspan="1" colspan="1">Personalized neoantigen vaccines, TCR-engineered T cells</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B82-vaccines-12-00950" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-12-00950" ref-type="bibr">83</xref>,<xref rid="B84-vaccines-12-00950" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutated antigens</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arise from mutations, creating novel peptides absent in normal cells.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IDH1 R132H in glioma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neoantigen vaccines, TCR-engineered T cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-vaccines-12-00950" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-12-00950" ref-type="bibr">83</xref>,<xref rid="B85-vaccines-12-00950" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-12-00950" ref-type="bibr">86</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>TAAs: tumor-associated antigens; TSAs: tumor-specific antigens; HER2: human epidermal growth factor receptor 2; MART-1: melanoma antigen recognized by T cells 1; NY-ESO-1: New York esophageal squamous cell carcinoma 1; CEA: carcinoembryonic antigen; IDH1 R132H: isocitrate dehydrogenase 1 (with the R132H mutation); HPV E6 and E7: human papillomavirus early proteins 6 and 7; KRAS G12D: Kirsten rat sarcoma viral oncogene homolog (with the G12D mutation).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-00950-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-00950-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary of the characteristics of peptide-based cancer vaccines in chronological order.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Applications</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disadvantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Development Time</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NY-ESO-1 Peptide Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets cancer-testis antigen NY-ESO-1.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma, ovarian cancer, sarcoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets a tumor-specific antigen, potential for broad application, immunogenic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited to NY-ESO-1-positive tumors, limited clinical data, ongoing clinical trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Late 1990s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-vaccines-12-00950" ref-type="bibr">120</xref>,<xref rid="B121-vaccines-12-00950" ref-type="bibr">121</xref>,<xref rid="B127-vaccines-12-00950" ref-type="bibr">127</xref>,<xref rid="B128-vaccines-12-00950" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MUC1 Peptide Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets MUC1 protein, which is overexpressed in adenocarcinomas.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer, pancreatic cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets a common cancer antigen, potential for broad application, immunogenic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited efficacy as monotherapy, high cost, ongoing clinical trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early 2000s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-vaccines-12-00950" ref-type="bibr">129</xref>,<xref rid="B130-vaccines-12-00950" ref-type="bibr">130</xref>,<xref rid="B131-vaccines-12-00950" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WT1 Peptide Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets WT1 protein to stimulate immune response.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AML, mesothelioma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets a universal cancer marker, potential broad application, immunogenic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited clinical data, ongoing clinical trials, variability in patient response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early 2000s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-vaccines-12-00950" ref-type="bibr">123</xref>,<xref rid="B132-vaccines-12-00950" ref-type="bibr">132</xref>,<xref rid="B133-vaccines-12-00950" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NeuVax (E75)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets HER2/neu-derived peptides to prevent recurrence.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Potential to prevent recurrence, targets specific antigen, combinable with other therapies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited to HER2-positive cancers, variability in patient response, ongoing clinical trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early 2000s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-vaccines-12-00950" ref-type="bibr">118</xref>,<xref rid="B134-vaccines-12-00950" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER-2/neu Peptide Vaccine (GP2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets HER2/neu protein, common in various cancers.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets specific cancer marker, potential to prevent recurrence, combinable with other therapies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited to HER2-positive cancers, variability in patient response, ongoing clinical trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early 2000s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-vaccines-12-00950" ref-type="bibr">118</xref>,<xref rid="B135-vaccines-12-00950" ref-type="bibr">135</xref>,<xref rid="B136-vaccines-12-00950" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAGE-A3 Peptide Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets MAGE-A3 antigen.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets specific cancer marker, potential for broad application, immunogenic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited to MAGE-A3-positive tumors, limited clinical data, ongoing clinical trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early 2000s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B122-vaccines-12-00950" ref-type="bibr">122</xref>,<xref rid="B137-vaccines-12-00950" ref-type="bibr">137</xref>,<xref rid="B138-vaccines-12-00950" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rindopepimut (CDX-110)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets EGFRvIII mutation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glioblastoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specific to tumor mutation, potential for personalized treatment, combinable with other therapies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited to EGFRvIII-positive tumors, limited clinical data, high cost</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early 2000s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-vaccines-12-00950" ref-type="bibr">139</xref>,<xref rid="B140-vaccines-12-00950" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IMA901</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multipeptide vaccine targeting multiple tumor-associated antigens.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal cell carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets multiple antigens, can be personalized, potential synergy with other therapies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited efficacy in monotherapy, not widely available, clinical trials ongoing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mid 2000s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-vaccines-12-00950" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-12-00950" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GV1001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets telomerase to provoke an immune response.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreatic cancer, NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets a universal cancer marker, potential broad application, immunogenic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited efficacy as monotherapy, high cost, side effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Late 2000s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-vaccines-12-00950" ref-type="bibr">115</xref>,<xref rid="B141-vaccines-12-00950" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IDH1 Peptide Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets mutant IDH1 protein.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glioma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specific to tumor mutation, potential for personalized treatment, immunogenic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited to IDH1-mutant tumors, limited clinical data, ongoing clinical trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Late 2000s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-vaccines-12-00950" ref-type="bibr">85</xref>,<xref rid="B142-vaccines-12-00950" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SurVaxM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets survivin to inhibit apoptosis and stimulate an immune response.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glioblastoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets a universal cancer marker, potential broad application, immunogenic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited clinical data, ongoing clinical trials, high cost</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early 2010s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-vaccines-12-00950" ref-type="bibr">143</xref>,<xref rid="B144-vaccines-12-00950" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KRAS Peptide Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targets mutant KRAS protein.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorectal cancer, pancreatic cancer, NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specific to tumor mutation, potential for personalized treatment, immunogenic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited to KRAS-mutant tumors, limited clinical data, ongoing clinical trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Late 2010s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B124-vaccines-12-00950" ref-type="bibr">124</xref>,<xref rid="B145-vaccines-12-00950" ref-type="bibr">145</xref>,<xref rid="B146-vaccines-12-00950" ref-type="bibr">146</xref>,<xref rid="B147-vaccines-12-00950" ref-type="bibr">147</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>AML: acute myeloid leukemia; EGFRvIII: epidermal growth factor receptor variant III; HER2/neu: human epidermal growth factor receptor 2; IDH1: isocitrate dehydrogenase 1; KRAS: Kirsten rat sarcoma viral oncogene homolog; MAGE-A3: melanoma antigen gene-A3; MUC1: mucin 1; NSCLC: non-small-cell lung cancer; NY-ESO-1: New York esophageal squamous cell carcinoma 1; WT1: Wilms tumor 1.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-00950-t003" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-00950-t003_Table 3</object-id><label>Table 3</label><caption><p>Summary of clinical trials of peptide tumor vaccines combined with targeted therapy, immunotherapy, and chemoradiotherapy in recent years.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Types of Combination Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Condition or Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Combination Therapy Drugs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Peptide-Based Tumor Vaccines</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Enrollment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment Effect</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Monotherapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Combined Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ClinicalTrials.gov ID</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide-based tumor vaccines and targeted therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced or metastatic renal cell carcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sunitinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IMA901</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1171 patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No improvement in OS (<italic toggle="yes">p</italic> = 0.087)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sunitinib monotherapy group Median OS (33.67 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sunitinib plus IMA901 group Median OS (33.17 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01265901">NCT01265901</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-vaccines-12-00950" ref-type="bibr">117</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Peptide-based tumor vaccines and immunotherapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Metastatic melanoma</td><td align="center" valign="middle" rowspan="1" colspan="1">Ipilimumab</td><td align="center" valign="middle" rowspan="1" colspan="1">gp100</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">676 patients</td><td align="center" valign="middle" rowspan="1" colspan="1">Improve OS (<italic toggle="yes">p</italic> &lt; 0.001)</td><td align="center" valign="middle" rowspan="1" colspan="1">gp100 monotherapy group <break/>Median OS (6.4 months months)</td><td align="center" valign="middle" rowspan="1" colspan="1">ipilimumab plus gp100 <break/>Median OS (10.0 months)</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00094653">NCT00094653</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B150-vaccines-12-00950" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human papillomavirus 16-related cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ISA101</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced tumoricidal effects</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">33% response rate and 17.5-month median OS versus PD-1 alone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02426892">NCT02426892</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B161-vaccines-12-00950" ref-type="bibr">161</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Peptide-based tumor vaccines and chemotherapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Locally advanced or metastatic pancreatic cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">Gemcitabine and capecitabine</td><td align="center" valign="middle" rowspan="1" colspan="1">GV1001</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">1062 patients</td><td align="center" valign="middle" rowspan="1" colspan="1">Do not significantly improve OS</td><td colspan="2" align="center" valign="middle" rowspan="1">Chemotherapy group (7.9 months); the sequential (6.9 months, HR 1.19); concurrent chemoimmunotherapy groups (8.4 months, HR 1.05)</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00425360">NCT00425360</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B141-vaccines-12-00950" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">EGFRvIII-expressing glioblastoma</td><td align="center" valign="middle" rowspan="1" colspan="1">Temozolomide</td><td align="center" valign="middle" rowspan="1" colspan="1">CDX-110</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">745 patients</td><td align="center" valign="middle" rowspan="1" colspan="1">Do not increase survival (<italic toggle="yes">p</italic> = 0.93)</td><td align="center" valign="middle" rowspan="1" colspan="1">temozolomide monotherapy group Median OS (20.0 months)</td><td align="center" valign="middle" rowspan="1" colspan="1">rindopepimut plus temozolomide Median OS (20.1 months)</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01480479">NCT01480479</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B140-vaccines-12-00950" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Advanced solid tumors</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyclophosphamide</td><td align="center" valign="middle" rowspan="1" colspan="1">RNF43</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">10 patients</td><td align="center" valign="middle" rowspan="1" colspan="1">Stable disease in six out of ten patients and an increase in tumor-reactive CD8+ T cells</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B162-vaccines-12-00950" ref-type="bibr">162</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biliary tract cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclophosphamide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Personalized peptide vaccination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49 patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significantly improved PFS (<italic toggle="yes">p</italic> = 0.008) and OS (<italic toggle="yes">p</italic> = 0.004)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">personalized peptide vaccination monotherapy group (PFS median time: 2.9 months; OS median time: 5.9 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low dose cyclophosphamide plus personalized peptide vaccination (PFS median time: 6.1 months; OS median time: 12.1 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B163-vaccines-12-00950" ref-type="bibr">163</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Peptide-based tumor vaccines and radiotherapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Esophageal cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">Cisplatin and 5-fluorouracil</td><td align="center" valign="middle" rowspan="1" colspan="1">TTK, URLC10, KOC1, VEGFR1, and VEGFR2</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">11 patients</td><td align="center" valign="middle" rowspan="1" colspan="1">Well tolerated, induced peptide-specific cytotoxic T-lymphocyte responses in all patients</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00632333">NCT00632333</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B156-vaccines-12-00950" ref-type="bibr">156</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced HCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">personalized peptide vaccination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Well tolerated, parts of patients&#8217; AFP levels decreased and their conditions stabilized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8211;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-vaccines-12-00950" ref-type="bibr">164</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein; OS: overall survival; PFS: progression-free survival.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-00950-t004" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-00950-t004_Table 4</object-id><label>Table 4</label><caption><p>Common clinical adjuvants and their characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Applications</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One of the oldest and most widely used adjuvants, including aluminum hydroxide and aluminum phosphate.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Forms a depot, enhances APC uptake, induces Th2 response.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis A and B, DTP vaccines.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B206-vaccines-12-00950" ref-type="bibr">206</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MF59</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An oil-in-water emulsion containing squalene.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhances APC recruitment and activation, balanced Th1/Th2 response.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza vaccines (e.g., Fluad).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B207-vaccines-12-00950" ref-type="bibr">207</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A combination of aluminum hydroxide and monophosphoryl lipid A.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulates TLR4, activates APCs, strong Th1 response.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV vaccine (Cervarix).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B208-vaccines-12-00950" ref-type="bibr">208</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG ODNs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synthetic oligodeoxynucleotides containing unmethylated CpG motifs that mimic bacterial DNA.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activates TLR9, cytokine production, strong Th1 response.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer and infectious disease vaccines.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B209-vaccines-12-00950" ref-type="bibr">209</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPLA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A detoxified derivative of LPS that retains immunostimulatory properties without toxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activates TLR4, enhances humoral and cell-mediated immunity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV vaccines (AS04 system).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B193-vaccines-12-00950" ref-type="bibr">193</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saponins (e.g., QS-21)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plant-derived compounds that form complexes with cholesterol to enhance immune responses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhances immune responses, stimulates Th1/Th2.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shingrix vaccine.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B210-vaccines-12-00950" ref-type="bibr">210</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toll-like receptor agonists</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compounds that mimic PAMPs to stimulate TLRs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activates TLRs, enhances innate and adaptive responses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer and infectious disease vaccines.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B211-vaccines-12-00950" ref-type="bibr">211</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GM-CSF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Granulocyte-macrophage colony-stimulating factor.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulates the production and activation of dendritic cells and macrophages.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma vaccines, various cancer immunotherapies.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B186-vaccines-12-00950" ref-type="bibr">186</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>HPV: human papillomavirus; PAMPs: pathogen-associated molecular patterns; ODNs: oligodeoxynucleotides; MPLA: monophosphoryl lipid A; LPS: lipopolysaccharide; TLR: Toll-like receptor; GM-CSF: granulocyte-macrophage colony-stimulating factor.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>